GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: June 15, 2004, 03:38:00 ; Search time 4864 Seconds
(without alignments)
10461.497 Million cell updates/sec

Title: US-09-978-299A-329
Perfect score: 1174
Sequence: 1 cggacgcgtgggggaaaccc.....taaagttactcaaatctgtg 1174

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 22

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database : GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rod:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1174	100.0	1174	6	AX454422	AX454422 Sequence
2	1174	100.0	1174	6	AX464138	AX464138 Sequence
3	1174	100.0	1174	6	AX490900	AX490900 Sequence
4	1174	100.0	1174	9	AY359029	AY359029 Homo sapi
5	1163.8	99.1	1634	6	BD127562	BD127562 Primer fo
6	1163.8	99.1	1634	9	AK075187	AK075187 Homo sapi
7	1163.8	99.1	1696	6	AX775907	AX775907 Sequence
8	1163.8	99.1	1704	6	BD210070	BD210070 Human tra
9	1163.8	99.1	1709	9	AF290615	AF290615 Homo sapi
10	1151.8	98.1	1695	6	BD191327	BD191327 186 human
11	1121	95.5	1121	6	BD233468	BD233468 Human pro
12	1118	95.2	1457	6	AX136301	AX136301 Sequence
13	1118	95.2	1457	6	BD123603	BD123603 Secretory
14	1118	95.2	1457	9	AK075505	AK075505 Homo sapi
15	1106	94.2	1138	6	AX683269	AX683269 Sequence
16	1106	94.2	1138	6	AX779812	AX779812 Sequence
17	1105	94.1	1466	6	AX775909	AX775909 Sequence
18	1105	94.1	1515	9	BC016374	BC016374 Homo sapi
19	1104	94.0	1130	9	BC003106	BC003106 Homo sapi
20	1049	89.4	1816	6	BD191202	BD191202 186 human
21	974	83.0	1742	6	AR379540	AR379540 Sequence
22	969	82.5	969	6	BD233458	BD233458 Human pro

ALIGNMENTS

RESULT 1
AX454422
LOCUS AX454422 1174 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 7 from Patent WO0208284.
ACCESSION AX454422
VERSION AX454422.1 GI:21713835
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Baker,K.P., Ferrara,N., Gerber,H., Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L., Hillan,K.J., Marsters,S.A., Pan,J., Paoni,N.F., Stephan,J.P., Watanabe,C.K., Williams,P.M., Wood,W.I. and Ye,W.
TITLE Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JOURNAL Patent: WO 0208284-A 7 31-JAN-2002;
Genentech, Inc. (US) ; Baker, Kevin P. (US) ; Ferrara, Napoleone (US) ; Gerber, Hanspeter (US) ; Gerritsen, Mary E. (US) ; Goddard, Audrey (US) ; Godowski, Paul J. (US) ; Gurney, Austin L. (US) ; Hillan, Kenneth J. (US) ; Marsters, Scot A. (US) ; Pan, James (US) ; Paoni, Nicholas F. (US) ; Stephan, Jean-Philippe F. (US) ; Watanabe, Colin K. (US) ; Williams, P. Mickey (US) ; Wood, William I. (US)
FEATURES Location/Qualifiers
source 1. .1174
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

```
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 2
AX464138
LOCUS AX464138 1174 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 271 from Patent WO0140466.
ACCESSION AX464138
VERSION AX464138.1 GI:21899085
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Baker,K.P., Beresini,M., Deforge,L., Desnoyers,L., Filvaroff,E.,
Gao,W.Q., Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L.,
Sherwood,S., Smith,V., Stewart,T.A., Tumas,D., Watanabe,C.K.,
Wood,W.L. and Zhang,Z.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
same
JOURNAL Patent: WO 0140466-A 271 07-JUN-2001;
Genentech Inc. (US)
FEATURES Location/Qualifiers
source 1. .1174
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
```

```
Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 3
AX490900
LOCUS       AX490900               1174 bp    DNA     linear   PAT 16-AUG-2002
DEFINITION  Sequence 7 from Patent WO0200690.
ACCESSION   AX490900
VERSION     AX490900.1  GI:22323787
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Baker,K.P., Ferrara,N., Gerber,H., Gerritsen,M.E., Goddard,A.,
            Godowski,P.J., Gurney,A.L., Hillan,K.J., Marsters,S.A., Pan,J.,
            Paoni,N.F., Stephan,J.P., Watanabe,C.K., Williams,P.M., Wood,W.I.
            and Ye,W.
  TITLE     Compositions and methods for the diagnosis and treatment of
            disorders involving angiogenesis
  JOURNAL   Patent: WO 0200690-A 7 03-JAN-2002;
            Genentech, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .1174
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
ORIGIN
```

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
```

```
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174

Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 4
AY359029

```
LOCUS       AY359029                1174 bp    mRNA    linear   PRI 03-OCT-2003
DEFINITION  Homo sapiens clone DNA26847 C1ORF8 (UNQ169) mRNA, complete cds.
ACCESSION   AY359029
VERSION     AY359029.1  GI:37183175
KEYWORDS    FLI_CDNA.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1174)
  AUTHORS   Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
            Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B.,
            Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
            Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
            Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
            Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
            Stinson,J., Vagts,A., Vandlen,R., Watanabe,C., Wieand,D., Woods,K.,
            Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
            Goddard,A., Wood,W.I. and Godowski,P.
  TITLE     The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
            Effort to Identify Novel Human Secreted and Transmembrane Proteins:
            A Bioinformatics Assessment
  JOURNAL   Genome Res. 13 (10), 2265-2270 (2003)
   PUBMED   12975309
REFERENCE   2  (bases 1 to 1174)
  AUTHORS   Clark,H.F.
  TITLE     Direct Submission
  JOURNAL   Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
            Inc., 1 DNA Way, South San Francisco, CA 94080, USA
FEATURES             Location/Qualifiers
     source          1. .1174
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="DNA26847"
     gene            1. .1174
                     /locus_tag="UNQ169"
     CDS             70. .1041
                     /locus_tag="UNQ169"
                     /note="PRO195"
                     /codon_start=1
                     /product="C1ORF8"
                     /protein_id="AAQ89388.1"
                     /db_xref="GI:37183176"
                     /translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
                     TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
                     AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
                     FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSYLQMRNSQAH
                     RNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
                     YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN
```

```
  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-274;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             ||||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 5
BD127562
LOCUS       BD127562                1634 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Primer for synthesizing full-length cDNA and use thereof.
ACCESSION   BD127562
VERSION     BD127562.1  GI:23222507
KEYWORDS    JP 2002017375-A/2993.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1634)
  AUTHORS   Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
            Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
            Koga,H.
  TITLE     Primer for synthesizing full-length cDNA and use thereof
  JOURNAL   Patent: JP 2002017375-A 2993 22-JAN-2002;
            HELIX RESEARCH INSTITUTE
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002017375-A/2993
            PD   22-JAN-2002
            PF   07-JUL-2000 JP 2000253172
            PI   TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
            PI   ISHII,
            PI   YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
            SHINICHI KOJIMA,
            PI   TETSUJI OTSUKI,HISASHI KOGA
            PC
            C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
             10,
            PC   C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
             Primer for synthesizing full-length cDNA and use thereof FH   Key
                    Location/Qualifiers
            FT   CDS             (191). .(1159).
FEATURES             Location/Qualifiers
     source          1. .1634
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
ORIGIN

  Query Match           99.1%;  Score 1163.8;  DB 6;  Length 1634;
  Best Local Similarity   99.8%;  Pred. No. 6.5e-272;
  Matches 1165;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
              | || ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        129 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 188

Qy         68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        189 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 248

Qy        128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        249 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 308

Qy        188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        309 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 368

Qy        248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        369 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 428

Qy        308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        429 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 488

Qy        368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        489 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 548

Qy        428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        549 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 608

Qy        488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        609 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 668

Qy        548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        669 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 728

Qy        608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        729 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 788

Qy        668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        789 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 848

Qy        728 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        849 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 908

Qy        788 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        909 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 968

Qy        848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        969 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 1028

Qy        908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1029 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 1088

Qy        968 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1089 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1148

Qy       1028 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1149 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1208

Qy       1088 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1147
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1209 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1268

Qy       1148 ATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||
Db       1269 ATGCAAATAAAGTTACTCAAATCTGTG 1295


RESULT 6
AK075187
LOCUS       AK075187                1634 bp    mRNA    linear   PRI 03-SEP-2002
DEFINITION  Homo sapiens cDNA FLJ90706 fis, clone PLACE1007626.
ACCESSION   AK075187
VERSION     AK075187.1  GI:22761112
KEYWORDS    oligo capping; fis (full insert sequence).
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Isogai,T., Ota,T., Nishikawa,T., Hayashi,K., Otsuki,T.,
            Sugiyama,T., Suzuki,Y., Nagai,K., Sugano,S., Ishii,S.,
            Kawai-Hio,Y., Saito,K., Yamamoto,J., Wakamatsu,A., Nakamura,Y.,
```

```
            Kojima,S., Nagahari,K., Masuho,Y., Ono,T., Okano,K., Yoshikawa,Y.,
            Aotsuka,S., Sasaki,N., Hattori,A., Okumura,K., Iwayanagi,T. and
            Ninomiya,K.
  TITLE     NEDO human cDNA sequencing project
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 1634)
  AUTHORS   Isogai,T. and Otsuki,T.
  TITLE     Direct Submission
  JOURNAL   Submitted (25-MAR-2002) Takao Isogai, Helix Research Institute,
            Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan
            (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
COMMENT     NEDO human cDNA sequencing project supported by Ministry of
            Economy, Trade and Industry of Japan; cDNA full insert sequencing:
            Research Association for Biotechnology; cDNA library construction:
            Institute of Medical Science, University of Tokyo, Laboratory of
            Genome Structure, Human Genome Center; cDNA 5'- & 3'-end one pass
            sequencing and clone selection: Helix Research Institute (supported
            by Japan Key Technology Center etc.).
FEATURES             Location/Qualifiers
     source          1. .1634
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="PLACE1007626"
                     /tissue_type="placenta"
                     /clone_lib="PLACE1"
                     /note="cloning vector: pME18SFL3"
ORIGIN

  Query Match             99.1%;  Score 1163.8;  DB 9;  Length 1634;
  Best Local Similarity   99.8%;  Pred. No. 6.5e-272;
  Matches 1165;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
              | || ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        129 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 188

Qy         68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        189 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 248

Qy        128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        249 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 308

Qy        188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        309 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 368

Qy        248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        369 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 428

Qy        308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        429 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 488

Qy        368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        489 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 548

Qy        428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        549 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 608

Qy        488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        609 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 668

Qy        548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        669 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 728

Qy        608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        729 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 788

Qy        668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        789 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 848

Qy        728 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        849 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 908

Qy        788 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        909 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 968

Qy        848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        969 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 1028

Qy        908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1029 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 1088

Qy        968 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1089 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1148

Qy       1028 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1149 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1208

Qy       1088 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1147
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1209 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1268

Qy       1148 ATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||
Db       1269 ATGCAAATAAAGTTACTCAAATCTGTG 1295


RESULT 7
AX775907
LOCUS       AX775907                1696 bp    mRNA    linear   PAT 14-JUL-2003
DEFINITION  Sequence 177 from Patent WO03048202.
ACCESSION   AX775907
VERSION     AX775907.1  GI:32693625
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Matsuda,A. and Muramatsu,S.
  TITLE     NF-kB activating gene
  JOURNAL   Patent: WO 03048202-A 177 12-JUN-2003;
            Asahi Kasei Kabushiki Kaisha (JP)
FEATURES             Location/Qualifiers
     source          1. .1696
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
     CDS             251. .1222
                     /note="unnamed protein product"
                     /codon_start=1
                     /protein_id="CAE11653.1"
                     /db_xref="GI:32693626"
                     /translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
                     TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
                     AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
                     FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSYLQMRNSQAH
                     RNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
                     YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
```

```
ORIGIN

  Query Match             99.1%;  Score 1163.8;  DB 6;  Length 1696;
  Best Local Similarity   99.8%;  Pred. No. 6.5e-272;
  Matches 1165;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
              | || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        189 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 248

Qy         68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        249 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 308

Qy        128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        309 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 368

Qy        188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        369 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 428

Qy        248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        429 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 488

Qy        308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        489 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 548

Qy        368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        549 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 608

Qy        428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        609 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 668

Qy        488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        669 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 728

Qy        548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        729 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 788

Qy        608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        789 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 848

Qy        668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        849 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 908

Qy        728 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        909 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 968

Qy        788 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        969 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 1028

Qy        848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1029 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 1088

Qy        908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1089 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 1148

Qy        968 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1149 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1208

Qy       1028 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1209 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1268

Qy       1088 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1147
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1269 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1328

Qy       1148 ATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||
Db       1329 ATGCAAATAAAGTTACTCAAATCTGTG 1355


RESULT 8
BD210070
LOCUS       BD210070                1704 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Human transmembrane protein.
ACCESSION   BD210070
VERSION     BD210070.1  GI:33019840
KEYWORDS    JP 2002516082-A/63.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1704)
  AUTHORS   Tang,T.Y., Lal,P., Hillman,J.L., Yue,H., Guegler,K.J., Corley,N.C.,
            Bandman,O., Patterson,C., Gorgone,G.A., Kaser,M.R., Baughn,M.R. and
            Young,J.A.
  TITLE     Human transmembrane protein
  JOURNAL   Patent: JP 2002516082-A 63 04-JUN-2002;
            INCYTE PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002516082-A/63
            PD   04-JUN-2002
            PF   28-MAY-1999 JP 2000550875
            PR   29-MAY-1998 US    60/087260,02-JUL-1998 US    60/091674 PR
            02-OCT-1998 US    60/102954,24-NOV-1998 US    60/109869 PI   TOM Y
            TANG,PREETI LAL,JENNIFER L HILLMAN,HENRY YUE,KARL J  PI   GUEGLER,
            PI   NEIL C CORLEY,OLGA BANDMAN,CHANDRA PATTERSON,GINA A GORGONE,
            PI   MATTHEW R KASER,MARIAH R BAUGHN,JANICE AU YOUNG PC
            C12N15/09,A61K38/00,A61K45/00,A61P1/04,A61P1/08,A61P1/10 PC
            ,A61P1/12,A61P1/16,
            PC   A61P3/10,A61P5/24,A61P7/02,A61P7/06,A61P9/10,A61P11/06 PC
            ,A61P15/08,A61P15/10,
            PC   A61P17/06,A61P19/02,A61P25/00,A61P25/06,A61P25/14,A61P25/16,
            PC   A61P25/28,
            PC   A61P31/04,A61P31/10,A61P31/12,A61P33/00,A61P35/00,A61P37/02,
            PC   C07K14/705,
            PC   C07K16/18,C12P21/02,C12Q1/68,G01N33/50,C12N15/00,A61K37/02 CC
             Incyte Clone No: 2454013
            FH   Key             Location/Qualifiers
            FT   source          1. .1704
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .1704
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
ORIGIN

  Query Match             99.1%;  Score 1163.8;  DB 6;  Length 1704;
  Best Local Similarity   99.8%;  Pred. No. 6.5e-272;
  Matches 1165;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
              | || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        183 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 242

Qy         68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        243 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 302
```

```
Qy       128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       303 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 362

Qy       188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       363 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 422

Qy       248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       423 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 482

Qy       308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       483 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 542

Qy       368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       543 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 602

Qy       428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       603 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 662

Qy       488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       663 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 722

Qy       548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       723 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 782

Qy       608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 667
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       783 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 842

Qy       668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 727
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       843 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 902

Qy       728 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 787
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       903 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 962

Qy       788 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 847
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       963 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 1022

Qy       848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 907
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1023 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 1082

Qy       908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 967
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1083 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 1142

Qy       968 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1143 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1202

Qy      1028 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1087
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1203 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1262

Qy      1088 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1147
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1263 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1322

Qy      1148 ATGCAAATAAAGTTACTCAAATCTGTG 1174
            ||||||||||||||||||||||||||
Db      1323 ATGCAAATAAAGTTACTCAAATCTGTG 1349
```

```
RESULT 9
AF290615
LOCUS       AF290615                1709 bp    mRNA    linear   PRI 01-APR-2001
DEFINITION  Homo sapiens clone E9271 liver membrane-bound protein mRNA,
            complete cds.
ACCESSION   AF290615
VERSION     AF290615.1  GI:13491977
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1709)
  AUTHORS   Qu,X., Zhang,C., Zhai,Y., Wu,S., Yu,Y., Wei,H., Xing,G., Lu,C.,
            Zhou,G., Dong,C. and He,F.
  TITLE     Homo sapiens liver membrane-bound protein mRNA
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 1709)
  AUTHORS   Qu,X., Zhang,C., Yu,Y., Wu,S., Wei,H., Xing,G., Zhai,Y., Lu,C.,
            Wang,M. and He,F.
  TITLE     Direct Submission
  JOURNAL   Submitted (28-JUL-2000) Department of Genomics and Proteomics,
            Institute of Radiation Medicine, Beijing Taiping Road 27, Beijing
            100850, P. R. China
FEATURES             Location/Qualifiers
     source          1. .1709
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /chromosome="1"
                     /map="1p33-p32.1"
                     /clone="E9271"
                     /tissue_type="liver"
                     /dev_stage="fetus"
     CDS             251. .1222
                     /note="LMBP; similar to mouse thymic dendritic
                     cell-derived factor 1"
                     /codon_start=1
                     /product="liver membrane-bound protein"
                     /protein_id="AAK28026.1"
                     /db_xref="GI:13491978"
                     /translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
                     TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
                     AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
                     FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSYLQMRNSQAH
                     RNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
                     YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN

  Query Match           99.1%;  Score 1163.8;  DB 9;  Length 1709;
  Best Local Similarity  99.8%;  Pred. No. 6.5e-272;
  Matches 1165;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
             | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       189 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 248

Qy        68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       249 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 308

Qy       128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       309 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 368

Qy       188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       369 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 428

Qy       248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       429 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 488
```

```
Qy        308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        489 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 548

Qy        368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        549 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 608

Qy        428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        609 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 668

Qy        488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        669 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 728

Qy        548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        729 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 788

Qy        608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        789 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 848

Qy        668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        849 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 908

Qy        728 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        909 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 968

Qy        788 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        969 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 1028

Qy        848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1029 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 1088

Qy        908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1089 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 1148

Qy        968 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1149 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1208

Qy       1028 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1209 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1268

Qy       1088 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1147
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1269 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1328

Qy       1148 ATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||
Db       1329 ATGCAAATAAAGTTACTCAAATCTGTG 1355


RESULT 10
BD191327
LOCUS       BD191327               1695 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  186 human secreted proteins.
ACCESSION   BD191327
VERSION     BD191327.1  GI:33001066
KEYWORDS    JP 2002510192-A/291.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 1695)
  AUTHORS   Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,
            Bednarik,D.P., Endress,G.A., Yu,G.L., N,J., Feng,P., Young,P.E.,
            Greene,J.M., Ferrie,A.M., Duan,R., Hu,J.S., Florence,K.A.,
            Olsen,H.S., Ebner,R., Brewer,L.A., Moore,P.A., Shi,Y.,
            Lafleur,D.W., Li,Y., Zeng,Z. and Kyaw,H.
  TITLE     186 human secreted proteins
  JOURNAL   Patent: JP 2002510192-A 291 02-APR-2002;
            HUMAN GENOME SCIENCES INC
COMMENT     PN   JP 2002510192-A/291
            PD   02-APR-2002
            PF   06-MAR-1998 JP 1998538883
            PR   07-MAR-1997 US    60/040162,07-MAR-1997 US    60/040333 PR
            07-MAR-1997 US    60/038621,07-MAR-1997 US    60/040161 PR
            07-MAR-1997 US    60/040626,07-MAR-1997 US    60/040334 PR
            07-MAR-1997 US    60/040336,07-MAR-1997 US    60/040163 PR
            11-APR-1997 US    60/043580,11-APR-1997 US    60/043568 PI   STEVEN
            M RUBEN,CRAIG A ROSEN,CARRIE L FISCHER,DANIEL R SOPPET, PI
            KENNETH C CARTER,DANIEL P BEDNARIK,GREGORY
            A ENDRESS,GUO LIANG
            PI   YU,JIAN NI,
            PI   PING FENG,PAUL E YOUNG,JOHN M GREENE,ANN
            M FERRIE,ROXANNE DUAN,
            PI   JING SHAN HU,KIMBERLY A FLORENCE,HENRIK
            S OLSEN,REINHARD EBNER,
            PI   LAURIE A BREWER,PAUL A MOORE,YANGGU SHI,DAVID W LAFLEUR PI
            ,YI LI,ZHIZHEN ZENG,
            PI   HLA KYAW
            PC   C12N15/12,C12N5/10,C12N1/21,C07K14/47,C07K16/18,C12Q1/68, PC
            G01N33/50,
            PC   G01N33/53,G01N33/68,A61K38/17
            CC   Strandedness: Double;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers.
FEATURES                Location/Qualifiers
     source             1. .1695
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"
ORIGIN

  Query Match             98.1%;  Score 1151.8;  DB 6;  Length 1695;
  Best Local Similarity   99.7%;  Pred. No. 5.4e-269;
  Matches 1164;  Conservative    0;  Mismatches    2;  Indels    1;  Gaps    1;

Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
              | || ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        167 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 226

Qy         68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
              ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||
Db        227 AGATGGCGGCGCCGAA-GGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 285

Qy        128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        286 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 345

Qy        188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        346 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 405

Qy        248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        406 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 465

Qy        308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        466 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 525

Qy        368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        526 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 585

Qy        428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        586 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 645

Qy        488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        646 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 705

Qy        548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        706 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 765

Qy        608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 667
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        766 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGA 825

Qy        668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 727
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        826 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGA 885

Qy        728 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 787
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        886 ATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGT 945

Qy        788 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 847
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        946 GGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAA 1005

Qy        848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 907
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1006 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACT 1065

Qy        908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 967
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1066 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTA 1125

Qy        968 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1126 GATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1185

Qy       1028 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1087
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1186 ATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCA 1245

Qy       1088 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1147
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1246 CTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAA 1305

Qy       1148 ATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||
Db       1306 ATGCAAATAAAGTTACTCAAATCTGTG 1332
```

```
RESULT 11
BD233468
LOCUS       BD233468                1121 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Human protein having hydrophobic domain and DNA encoding the same.
ACCESSION   BD233468
VERSION     BD233468.1  GI:33043238
KEYWORDS    JP 2002519016-A/14.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1121)
  AUTHORS   Kato,S. and Kimura,T.
  TITLE     Human protein having hydrophobic domain and DNA encoding the same
  JOURNAL   Patent: JP 2002519016-A 14 02-JUL-2002;
            SAGAMI CHEMICAL RESEARCH CENTER,PROTEGENE INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002519016-A/14
            PD   02-JUL-2002
            PF   18-JUN-1999 JP 2000557267
            PI   SEISHI KATO,TOMOKO KIMURA
            PC   C12N15/09,C07K14/47,C12N1/15,C12N1/19,C12N5/10,C12N15/00,C12N5/ PC
             00
            CC   Human protein having hydrophobic domain and DNA encoding the
            CC            same
            FH   Key             Location/Qualifiers
            FT   source          1. .1121
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .1121
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
ORIGIN

  Query Match             95.5%;  Score 1121;  DB 6;  Length 1121;
  Best Local Similarity   100.0%;  Pred. No. 1.6e-261;
  Matches 1121;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          54 GACAGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGG 113
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 GACAGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGG 60

Qy         114 GCTCCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGC 173
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 GCTCCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGC 120

Qy         174 TGAAGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGAC 233
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 TGAAGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGAC 180

Qy         234 CTACCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAG 293
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 CTACCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAG 240

Qy         294 GCTGTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGA 353
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         241 GCTGTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGA 300

Qy         354 ATGTGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCT 413
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         301 ATGTGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCT 360

Qy         414 TGGTTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGAT 473
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         361 TGGTTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGAT 420

Qy         474 GCCAAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGAT 533
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         421 GCCAAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGAT 480

Qy         534 GGACTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGG 593
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         481 GGACTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGG 540

Qy         594 AAAAATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGA 653
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         541 AAAAATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGA 600

Qy         654 GCCTACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTC 713
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         601 GCCTACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTC 660

Qy         714 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTC 773
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         661 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTC 720

Qy         774 TCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTG 833
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         721 TCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTG 780

Qy         834 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 893
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         781 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 840
```

```
Qy        894 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 953
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 900

Qy        954 TCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 1013
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 TCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 960

Qy       1014 AGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGA 1073
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 AGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGA 1020

Qy       1074 CATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAA 1133
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1021 CATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAA 1080

Qy       1134 GAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||||||||
Db        1081 GAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1121
```

RESULT 12
AX136301

```
LOCUS       AX136301               1457 bp    DNA     linear   PAT 30-MAY-2001
DEFINITION  Sequence 223 from Patent EP1067182.
ACCESSION   AX136301
VERSION     AX136301.1  GI:14272707
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Ota,T., Isogai,T., Nishikawa,T., Kawai,Y., Sugiyama,T. and
            Hayashi,K.
  TITLE     Secretory protein or membrane protein
  JOURNAL   Patent: EP 1067182-A 223 10-JAN-2001;
            Helix Research Institute (JP)
FEATURES             Location/Qualifiers
     source          1. .1457
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     CDS             14. .985
                     /note="unnamed protein product"
                     /codon_start=1
                     /protein_id="CAC39792.1"
                     /db_xref="GI:14272708"
                     /db_xref="REMTREMBL:CAC39792"
                     /translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
                     TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
                     AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
                     FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSYLQMRNSQAH
                     RNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
                     YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN
```

```
  Query Match             95.2%;  Score 1118;  DB 6;  Length 1457;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-261;
  Matches 1118;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 60

Qy         117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 120

Qy         177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 180

Qy         237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 240

Qy         297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         241 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 300

Qy         357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         301 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 360

Qy         417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         361 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 420

Qy         477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         421 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 480

Qy         537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         481 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 540

Qy         597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         541 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 600

Qy         657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 716
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         601 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 660

Qy         717 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 776
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         661 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 720

Qy         777 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 836
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         721 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 780

Qy         837 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         781 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 840

Qy         897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         841 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 900

Qy         957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 1016
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         901 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 960

Qy        1017 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1076
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         961 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1020

Qy        1077 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1136
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1021 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1080

Qy        1137 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
               |||||||||||||||||||||||||||||||||||||
Db        1081 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1118
```

RESULT 13
BD123603

```
LOCUS       BD123603               1457 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Secretory protein or membrane protein.
ACCESSION   BD123603
VERSION     BD123603.1  GI:23218548
KEYWORDS    JP 2002017376-A/112.
```

```
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1457)
  AUTHORS   Ota,T., Isogai,T., Nishikawa,T., Kawai,Y., Sugiyama,T. and
            Hayashi,K.
  TITLE     Secretory protein or membrane protein
  JOURNAL   Patent: JP 2002017376-A 112 22-JAN-2002;
            HELIX RESEARCH INSTITUTE
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002017376-A/112
            PD   22-JAN-2002
            PF   07-JUL-2000 JP 2000253173
            PI   TOSHIO OTA,TAKAO ISOGAI,TETSUO NISHIKAWA,YURI KAWAI,TOMOYASU
            PI   SUGIYAMA,
            PI   KOJI HAYASHI
            PC
            C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
             10,
            PC   C12P21/02,C12Q1/68//C12P21/08,C12N15/00,C12N5/00 CC
            Secretory protein or membrane protein
            FH   Key             Location/Qualifiers
            FT   CDS             (14). .(982).
FEATURES            Location/Qualifiers
     source         1. .1457
                    /organism="Homo sapiens"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:9606"
ORIGIN

  Query Match             95.2%;  Score 1118;  DB 6;  Length 1457;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-261;
  Matches 1118;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 60

Qy        117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 120

Qy        177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 180

Qy        237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 240

Qy        297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 300

Qy        357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 360

Qy        417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 420

Qy        477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 480

Qy        537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 540

Qy        597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db        541 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 600

Qy        657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 716
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 660

Qy        717 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 776
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 720

Qy        777 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 836
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 780

Qy        837 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 840

Qy        897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 900

Qy        957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 1016
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 960

Qy       1017 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1076
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1020

Qy       1077 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1136
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1080

Qy       1137 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||||
Db       1081 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1118


RESULT 14
AK075505
LOCUS       AK075505                1457 bp    mRNA    linear   PRI 03-SEP-2002
DEFINITION  Homo sapiens cDNA PSEC0203 fis, clone HEMBA1002441.
ACCESSION   AK075505
VERSION     AK075505.1  GI:22761691
KEYWORDS    oligo capping; fis (full insert sequence).
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Ota,T., Nishikawa,T., Suzuki,Y., Kawai-Hio,Y., Hayashi,K.,
            Ishii,S., Saito,K., Yamamoto,J., Wakamatsu,A., Nagai,T.,
            Nakamura,Y., Nagahari,K., Sugano,S. and Isogai,T.
  TITLE     HRI human cDNA sequencing project
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 1457)
  AUTHORS   Isogai,T. and Yamamoto,J.
  TITLE     Direct Submission
  JOURNAL   Submitted (20-MAR-2002) Takao Isogai, Helix Research Institute,
            Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan
            (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
COMMENT     HRI human cDNA sequencing project; cDNA 5'- & 3'-end one pass
            sequencing, clone selection and full insert sequencing: Helix
            Research Institute (supported by Japan Key Technology Center etc.);
            cDNA library construction: Institute of Medical Science, University
            of Tokyo, Laboratory of Genome Structure, Human Genome Center.
FEATURES            Location/Qualifiers
     source         1. .1457
                    /organism="Homo sapiens"
                    /mol_type="mRNA"
                    /db_xref="taxon:9606"
                    /clone="HEMBA1002441"
```

```
                     /tissue_type="whole embryo, mainly head"
                     /clone_lib="HEMBA1"
                     /dev_stage="embryo, 10 weeks"
                     /note="cloning vector: pME18SFL3"
     CDS             14. .985
                     /note="unnamed protein product"
                     /codon_start=1
                     /protein_id="BAC11658.1"
                     /db_xref="GI:22761692"
                     /translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
                     TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
                     AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
                     FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSYLQMRNSQAH
                     RNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
                     YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN

  Query Match             95.2%;  Score 1118;  DB 9;  Length 1457;
  Best Local Similarity   100.0%;  Pred. No. 8.8e-261;
  Matches 1118;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 60

Qy        117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 120

Qy        177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 180

Qy        237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 240

Qy        297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 300

Qy        357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 360

Qy        417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 420

Qy        477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 480

Qy        537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 540

Qy        597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 600

Qy        657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 716
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 660

Qy        717 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 776
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 720

Qy        777 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 836
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 780

Qy        837 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 840

Qy        897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 900

Qy        957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 1016
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 960

Qy       1017 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1076
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         961 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1020

Qy       1077 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1136
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1021 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1080

Qy       1137 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||||||
Db        1081 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1118


RESULT 15
AX683269
LOCUS       AX683269                1138 bp    DNA     linear   PAT 29-MAR-2003
DEFINITION  Sequence 13 from Patent WO03006687.
ACCESSION   AX683269
VERSION     AX683269.1  GI:29370420
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Reuner,B., Bunk,D. and Henkel,T.
  TITLE     Novel target genes for diseases of the heart
  JOURNAL   Patent: WO 03006687-A 13 23-JAN-2003;
            Medigene AG (DE)
FEATURES             Location/Qualifiers
     source          1. .1138
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
ORIGIN

  Query Match             94.2%;  Score 1106;  DB 6;  Length 1138;
  Best Local Similarity   99.9%;  Pred. No. 7.1e-258;
  Matches 1117;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    1;

Qy         57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116
              |||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||
Db          3 AGAGGGGAACAAGATGGCGGCGCCGAA-GGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 61

Qy        117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 121

Qy        177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        122 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 181

Qy        237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        182 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 241

Qy        297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        242 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 301

Qy        357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
```

```
Db        302 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 361

Qy        417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476

Db        362 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 421

Qy        477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536

Db        422 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 481

Qy        537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596

Db        482 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 541

Qy        597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656

Db        542 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 601

Qy        657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 716

Db        602 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 661

Qy        717 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 776

Db        662 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 721

Qy        777 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 836

Db        722 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 781

Qy        837 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896

Db        782 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 841

Qy        897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956

Db        842 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 901

Qy        957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 1016

Db        902 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 961

Qy       1017 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1076

Db        962 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1021

Qy       1077 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1136

Db       1022 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1081

Qy       1137 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174

Db       1082 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1119
```

```
RESULT 16
AX779812
LOCUS       AX779812               1138 bp    DNA     linear   PAT 14-JUL-2003
DEFINITION  Sequence 1969 from Patent WO03039443.
ACCESSION   AX779812
VERSION     AX779812.1  GI:32696806
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Haferlach,T., Schoch,C., Kern,W., Kohlmann,A., Schnittger,S.,
            Dugas,M., Eils,R., Brors,B. and Mergenthaler,S.
  TITLE     Novel genetic markers for leukemias
  JOURNAL   Patent: WO 03039443-A 1969 15-MAY-2003;
            Deutsches Krebsforschungszentrum (DE) ;
            Ludwig-Maximilian-Universitaet Muenchen (DE) ; Haferlach, Torsten,
            PD Dr. Dr. (DE) ; Schoch, Claudia (DE) ; Kern, Wolfgang (DE)
FEATURES             Location/Qualifiers
     source          1. .1138
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
ORIGIN

  Query Match             94.2%;  Score 1106;  DB 6;  Length 1138;
  Best Local Similarity   99.9%;  Pred. No. 7.1e-258;
  Matches 1117;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    1;

Qy         57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116

Db          3 AGAGGGGAACAAGATGGCGGCGCCGAA-GGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 61

Qy        117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176

Db         62 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 121

Qy        177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236

Db        122 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 181

Qy        237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296

Db        182 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 241

Qy        297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356

Db        242 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 301

Qy        357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416

Db        302 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 361

Qy        417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476

Db        362 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 421

Qy        477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536

Db        422 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 481

Qy        537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596

Db        482 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 541

Qy        597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656

Db        542 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 601

Qy        657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 716

Db        602 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACA 661

Qy        717 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 776

Db        662 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCT 721

Qy        777 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 836

Db        722 TAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGAT 781

Qy        837 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896

Db        782 TTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 841

Qy        897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956

Db        842 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 901
```

```
Qy        957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 1016
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        902 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 961

Qy       1017 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1076
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        962 GAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACAT 1021

Qy       1077 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1136
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1022 CTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAA 1081

Qy       1137 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||||
Db       1082 ATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1119
```

RESULT 17
AX775909

```
LOCUS       AX775909               1466 bp    mRNA    linear   PAT 14-JUL-2003
DEFINITION  Sequence 179 from Patent WO03048202.
ACCESSION   AX775909
VERSION     AX775909.1  GI:32693627
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Matsuda,A. and Muramatsu,S.
  TITLE     NF-kB activating gene
  JOURNAL   Patent: WO 03048202-A 179 12-JUN-2003;
            Asahi Kasei Kabushiki Kaisha (JP)
FEATURES             Location/Qualifiers
     source          1. .1466
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
     CDS             18. .992
                     /note="unnamed protein product"
                     /codon_start=1
                     /protein_id="CAE11654.1"
                     /db_xref="GI:32693628"
                     /translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
                     TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
                     AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
                     FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSSDLQMRNSQA
                     HRNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLS
                     IYGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN
```

```
  Query Match             94.1%;  Score 1105;  DB 6;  Length 1466;
  Best Local Similarity   99.7%;  Pred. No. 1.3e-257;
  Matches 1118;  Conservative    0;  Mismatches    0;  Indels    3;  Gaps    1;

Qy          57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           5 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 64

Qy         117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          65 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 124

Qy         177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         125 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 184

Qy         237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         185 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 244

Qy         297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         245 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 304

Qy         357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         305 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 364

Qy         417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         365 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 424

Qy         477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         425 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 484

Qy         537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         485 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 544

Qy         597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         545 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 604

Qy         657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCT---ATCTGCAAATGAGAAATTC 713
               ||||||||||||||||||||||||||||||||||||   |||||||||||||||||||
Db         605 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTCAGATCTGCAAATGAGAAATTC 664

Qy         714 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTC 773
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         665 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTC 724

Qy         774 TCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTG 833
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         725 TCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTG 784

Qy         834 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 893
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         785 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 844

Qy         894 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 953
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         845 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 904

Qy         954 TCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 1013
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         905 TCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 964

Qy        1014 AGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGA 1073
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         965 AGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGA 1024

Qy        1074 CATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAA 1133
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1025 CATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAA 1084

Qy        1134 GAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
               |||||||||||||||||||||||||||||||||||||||||
Db        1085 GAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1125
```

RESULT 18
BC016374

```
LOCUS       BC016374               1515 bp    mRNA    linear   PRI 12-NOV-2003
DEFINITION  Homo sapiens chromosome 1 open reading frame 8, mRNA (cDNA clone
            MGC:27259 IMAGE:4618034), complete cds.
ACCESSION   BC016374
VERSION     BC016374.1  GI:16741047
KEYWORDS    MGC.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1515)
  AUTHORS   Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
```

Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D., Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K., Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F., Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L., Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L., Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S., Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J., Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J., McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S., Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W., Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A., Fahey,J., Helton,E., Ketteman,M., Madan,A., Rodrigues,S., Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y., Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D., Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M., Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smailus,D.E., Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.

TITLE Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

MEDLINE 22388257

PUBMED 12477932

REFERENCE 2 (bases 1 to 1515)

AUTHORS Strausberg,R.

TITLE Direct Submission

JOURNAL Submitted (29-OCT-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov

COMMENT Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: CLONTECH
cDNA Library Preparation: CLONTECH Laboratories, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.systemsbiology.org
contact: amadan@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Ketteman, Anuradha Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAL Plate: 38 Row: e Column: 10.

FEATURES Location/Qualifiers

source 1. .1515
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:27259 IMAGE:4618034"
/tissue_type="Lung"
/clone_lib="NIH_MGC_77"
/lab_host="DH10B"
/note="Vector: pDNR-LIB"

gene 1. .1515
/gene="C1orf8"
/note="synonym: HSPC001"
/db_xref="LocusID:9528"

CDS 18. .992
/codon_start=1
/product="thymic dendritic cell-derived factor 1"
/protein_id="AAH16374.1"
/db_xref="GI:16741048"
/db_xref="LocusID:9528"
/translation="MAAPKGSLWVRTQLGLPPLLLLTMALAGGSGTASAEAFDSVLGD
TASCHRACQLTYPLHTYPKEEELYACQRGCRLFSICQFVDDGIDLNRTKLECESACTE
AYSQSDEQYACHLGCQNQLPFAELRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQS
FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQEPTNLRESSLSKMSSDLQMRNSQA
HRNFLEDGESDGFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLS
IYGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"

ORIGIN

Query Match 94.1%; Score 1105; DB 9; Length 1515;

Best Local Similarity 99.7%; Pred. No. 1.3e-257;
Matches 1118; Conservative 0; Mismatches 0; Indels 3; Gaps 1;

```
Qy      57 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 116
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       5 AGAGGGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT 64

Qy     117 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 176
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      65 CCCGCCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGA 124

Qy     177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 236
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     125 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTA 184

Qy     237 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 296
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     185 CCCCTTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCT 244

Qy     297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 356
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     245 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG 304

Qy     357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     305 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 364

Qy     417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     365 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 424

Qy     477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     425 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 484

Qy     537 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 596
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     485 CTCCGCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAA 544

Qy     597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 656
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     545 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCC 604

Qy     657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCT---ATCTGCAAATGAGAAATTC 713
           |||||||||||||||||||||||||||||||||||||   |||||||||||||||||||
Db     605 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCCTCAGATCTGCAAATGAGAAATTC 664

Qy     714 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTC 773
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     665 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTC 724

Qy     774 TCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTG 833
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     725 TCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTG 784

Qy     834 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 893
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     785 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 844

Qy     894 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 953
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     845 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 904

Qy     954 TCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 1013
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     905 TCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 964

Qy    1014 AGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGA 1073
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     965 AGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGA 1024

Qy    1074 CATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAA 1133
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db       1025 CATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAA 1084

Qy       1134 GAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||||||||||
Db       1085 GAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1125


RESULT 19
BC003106
LOCUS       BC003106                1130 bp    mRNA    linear   PRI 03-OCT-2003
DEFINITION  Homo sapiens chromosome 1 open reading frame 8, mRNA (cDNA clone
            MGC:1961 IMAGE:3501639), complete cds.
ACCESSION   BC003106
VERSION     BC003106.1  GI:13111876
KEYWORDS    MGC.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1130)
  AUTHORS   Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
            Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
            Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
            Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
            Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
            Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
            Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
            Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
            Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
            McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
            Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
            Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
            Fahey,J., Helton,E., Ketteman,M., Madan,A., Rodrigues,S.,
            Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
            Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
            Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
            Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smailus,D.E.,
            Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
  TITLE     Generation and initial analysis of more than 15,000 full-length
            human and mouse cDNA sequences
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
  MEDLINE   22388257
   PUBMED   12477932
REFERENCE   2  (bases 1 to 1130)
  AUTHORS   Strausberg,R.
  TITLE     Direct Submission
  JOURNAL   Submitted (13-FEB-2001) National Institutes of Health, Mammalian
            Gene Collection (MGC), Cancer Genomics Office, National Cancer
            Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
            USA
  REMARK    NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT     Contact: MGC help desk
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: ATCC
            cDNA Library Preparation: Rubin Laboratory
            cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
            DNA Sequencing by: Genome Sequence Centre,
            BC Cancer Agency, Vancouver, BC, Canada
            info@bcgsc.bc.ca
            Steven Jones, Jennifer Asano, Ian Bosdet, Yaron Butterfield,
            Susanna Chan, Readman Chiu, Chris Fjell, Erin Garland, Ran Guin,
            Letticia Hsiao, Martin Krzywinski, Reta Kutsche, Oliver Lee, Soo
            Sen Lee, Victor Ling, Carrie Mathewson, Candice McLeavy, Steven
            Ness, Pawan Pandoh, Anna-Liisa Prabhu, Parvaneh Saeedi, Jacqueline
            Schein, Duane Smailus, Michael Smith, Lorraine Spence, Jeff Stott,
            Michael Thorne, Miranada Tsai, Natasja van den Bosch, Jill Vardy,
            George Yang, Scott Zuyderduyn, Marco Marra.

            Clone distribution: MGC clone distribution information can be found
            through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
            Series: IRAL Plate: 6 Row: j Column: 2
            This clone was selected for full length sequencing because it
            passed the following selection criteria: matched mRNA gi: 20070190.

FEATURES             Location/Qualifiers
     source          1. .1130
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="MGC:1961 IMAGE:3501639"
                     /tissue_type="Brain, neuroblastoma"
                     /clone_lib="NIH_MGC_19"
                     /lab_host="DH10B-R"
                     /note="Vector: pOTB7"
     gene            1. .1130
                     /gene="C1orf8"
                     /note="synonym: HSPC001"
                     /db_xref="LocusID:9528"
     CDS             69. .971
                     /codon_start=1
                     /product="C1orf8 protein"
                     /protein_id="AAH03106.1"
                     /db_xref="GI:13111877"
                     /db_xref="LocusID:9528"
                     /translation="MALAGGSGTASAEAFDSVLGDTASCHRACQLTYPLHTYPKEEEL
                     YACQRGCRLFSICQFVDDGIDLNRTKLECESACTEAYSQSDEQYACHLGCQNQLPFAE
                     LRQEQLMSLMPKMHLLFPLTLVRSFWSDMMDSAQSFITSSWTFYLQADDGKIVIFQSK
                     PEIQYAPHLEQEPTNLRESSLSKMSYLQMRNSQAHRNFLEDGESDGFLRCLSLNSGWI
                     LTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSIYGDLEFMNEQKLNRYPASSLVVV
                     RSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN

  Query Match             94.0%;  Score 1104;  DB 9;  Length 1130;
  Best Local Similarity   100.0%;  Pred. No. 2.2e-257;
  Matches 1104;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         71 TGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGCTGC 130
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 TGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGCTGC 60

Qy        131 TGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACTCGG 190
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 TGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACTCGG 120

Qy        191 TCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACACCT 250
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACACCT 180

Qy        251 ACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTTGTC 310
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 ACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTTGTC 240

Qy        311 AGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCATGTA 370
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCATGTA 300

Qy        371 CAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATCAGC 430
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 CAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATCAGC 360

Qy        431 TGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACCTAC 490
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACCTAC 420

Qy        491 TCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGAGCT 550
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 TCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGAGCT 480

Qy        551 TCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATTCC 610
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 TCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATTCC 540

Qy        611 AGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGAGAG 670
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 AGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGAGAG 600

Qy        671 AATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGAATT 730
```

```
Db        601 AATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGAATT 660

Qy        731 TTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGTGGA 790
Db        661 TTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGTGGA 720

Qy        791 TTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAACTG 850
Db        721 TTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAACTG 780

Qy        851 TTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACTTGG 910
Db        781 TTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACTTGG 840

Qy        911 AGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTAGAT 970
Db        841 AGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTAGAT 900

Qy        971 CTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTCATT 1030
Db        901 CTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTCATT 960

Qy       1031 CTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCACTC 1090
Db        961 CTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAAAATTCCACTC 1020

Qy       1091 CTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAAATG 1150
Db       1021 CTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCACTATAAAATG 1080

Qy       1151 CAAATAAAGTTACTCAAATCTGTG 1174
Db       1081 CAAATAAAGTTACTCAAATCTGTG 1104
```

```
RESULT 20
BD191202
LOCUS       BD191202                1816 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  186 human secreted proteins.
ACCESSION   BD191202
VERSION     BD191202.1  GI:33000941
KEYWORDS    JP 2002510192-A/166.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 1816)
  AUTHORS   Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,
            Bednarik,D.P., Endress,G.A., Yu,G.L., N,J., Feng,P., Young,P.E.,
            Greene,J.M., Ferrie,A.M., Duan,R., Hu,J.S., Florence,K.A.,
            Olsen,H.S., Ebner,R., Brewer,L.A., Moore,P.A., Shi,Y.,
            Lafleur,D.W., Li,Y., Zeng,Z. and Kyaw,H.
  TITLE     186 human secreted proteins
  JOURNAL   Patent: JP 2002510192-A 166 02-APR-2002;
            HUMAN GENOME SCIENCES INC
COMMENT     PN   JP 2002510192-A/166
            PD   02-APR-2002
            PF   06-MAR-1998 JP 1998538883
            PR   07-MAR-1997 US    60/040162,07-MAR-1997 US    60/040333 PR
            07-MAR-1997 US    60/038621,07-MAR-1997 US    60/040161 PR
            07-MAR-1997 US    60/040626,07-MAR-1997 US    60/040334 PR
            07-MAR-1997 US    60/040336,07-MAR-1997 US    60/040163 PR
            11-APR-1997 US    60/043580,11-APR-1997 US    60/043568 PI   STEVEN
            M RUBEN,CRAIG A ROSEN,CARRIE L FISCHER,DANIEL R SOPPET, PI
            KENNETH C CARTER,DANIEL P BEDNARIK,GREGORY
            A ENDRESS,GUO LIANG
            PI   YU,JIAN NI,
            PI   PING FENG,PAUL E YOUNG,JOHN M GREENE,ANN
            M FERRIE,ROXANNE DUAN,
            PI   JING SHAN HU,KIMBERLY A FLORENCE,HENRIK
            S OLSEN,REINHARD EBNER,
            PI   LAURIE A BREWER,PAUL A MOORE,YANGGU SHI,DAVID W LAFLEUR PI
            ,YI LI,ZHIZHEN ZENG,
            PI   HLA KYAW
            PC   C12N15/12,C12N5/10,C12N1/21,C07K14/47,C07K16/18,C12Q1/68, PC
            G01N33/50,
            PC   G01N33/53,G01N33/68,A61K38/17
            CC   Strandedness: Double;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers.
FEATURES                Location/Qualifiers
     source             1. .1816
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"
ORIGIN
```

Query Match 89.4%; Score 1049; DB 6; Length 1816;
Best Local Similarity 94.7%; Pred. No. 5.3e-244;
Matches 1119; Conservative 11; Mismatches 37; Indels 15; Gaps 4;

```
Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
Db        222 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 281

Qy         68 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
Db        282 AGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 341

Qy        128 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
Db        342 TGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACT 401

Qy        188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 247
Db        402 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACA 461

Qy        248 CCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 307
Db        462 CCTACCCTAAGGAAGAAGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTT 521

Qy        308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 367
Db        522 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCAT 581

Qy        368 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATC 427
Db        582 GTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGKTGCCAGAATC 641

Qy        428 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 487
Db        642 AGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACC 701

Qy        488 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 547
Db        702 TACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGA 761

Qy        548 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
Db        762 GCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 821

Qy        608 TCCAGTCTAAGCC---AGAAATCCAGTACGCACCACATTTGGAGC---AGGAGCCTACAA 661
Db        822 TCCRGTCTAAGCCCAGRAATCCCAGGTACGCACCACATTTGGAGCCAGGAGCCCTACCAA 881

Qy        662 ATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCT---GCAAATGAGAAATTCACAAG 718
Db        882 ATTTGRGRGRAWCMTCTCTAAGCAAAATGTCCNTCAKMTCGSMAATGAGAAATTCACAAG 941

Qy        719 CGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTA 778
Db        942 CGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTA 1001

Qy        779 ACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTT 838
Db       1002 ACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTT 1061
```

```
Qy        839 GTTGTGCAACTGTTGCTACAGCTGTGGAGCA------GTATGTTCCCTCTGAGAAGCTGA 892
              ||||||||||| |         | ||  ||        ||  |||||||||||||||||||
Db       1062 GTTGTGCAACTTGTTGCTACACGCTGTTGGACGCAGTATAGTTTCCCTCTGAGAAGCTGA 1121

Qy        893 GTATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTT 952
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1122 GTATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTT 1181

Qy        953 CTCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAA 1012
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1182 CTCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAA 1241

Qy        1013 AAGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAG 1072
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1242 AAGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAG 1301

Qy        1073 ACATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTA 1132
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1302 ACATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTA 1361

Qy        1133 AGAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
               |||||||||||||||||||||||||||||||||||||||||||
Db       1362 AGAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1403
```

```
RESULT 21
AR379540
LOCUS       AR379540                1742 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 85 from patent US 6607879.
ACCESSION   AR379540
VERSION     AR379540.1  GI:40087174
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 1742)
  AUTHORS   Cocks,B.G., Stuart,S.G. and Seilhamer,J.J.
  TITLE     Compositions for the detection of blood cell and immunological
            response gene expression
  JOURNAL   Patent: US 6607879-A 85 19-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .1742
                     /organism="unknown"
                     /mol_type="genomic DNA"
ORIGIN

  Query Match             83.0%;  Score 974;  DB 6;  Length 1742;
  Best Local Similarity   97.1%;  Pred. No. 9e-226;
  Matches 1152;  Conservative    0;  Mismatches   15;  Indels   19;  Gaps   15;
```

```
Qy          8 GTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGC-TGTGACAGAGGGGAAC 66
              | || ||||||||||||||||||||||||||||||||||||| |||||||||||||||||
Db        154 GAGGAGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTTGTGACAGAGGGGAAC 213

Qy         67 AAGATGGCGGCGCCGAAGGG-GAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCT 125
              |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Db        214 AAGATGGCGGCGCCGAAGGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCT 273

Qy        126 GCTGCTGCTGACCATGGCCTTGGCCGGAGG-TTCGGGGACCGCTTCGGCTGAAGCATTTG 184
              |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db        274 GCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCATTTG 333

Qy        185 ACTCGGTCTTGGGTGATACGGCGTCTTGCC-ACCGGGCCTGTCAGTTGACCTACCCCTTG 243
              |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db        334 ACTCGGTCTTGGGTGATACGGCGTCTTGCCAACCGGGCCTGTCAGTTGACCTACCCCTTG 393

Qy        244 CACACCTACCCTAA-GGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGC-AGGCTGTTTT 301
              |||||||||||||| |||||||||||||||||||||||||||||||| | ||||||||||
Db        394 CACACCTACCCTAAGGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTTCAAGGCTGTTTT 453

Qy        302 CAA--TTTGTCAGTTTGTGGATGATGGAA-TTGACTTAAATCGAACTAAATTGGAATGTG 358
              |||  ||    ||||| |||||||||||| |||||||||||||||||||||||||||||
```

```
Db        454 CAAATTTGTCAAGTTTCTGGATGATGGAATTTGACTTAAATCGAACTAAATTGGAATGTG 513

Qy        359 AATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTT--GCCATCTTGG 416
              |||||||||||||||||||||||||||||||||||||||||||||||  ||| |||||||
Db        514 AATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTTGCCAACTTGGT 573

Qy        417 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 476
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        574 TTGCCAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCC 633

Qy        477 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 536
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        634 AAAAATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGA 693

Qy        537 CTCCGCACAGAGCTTCATAACCTC-TTCATGGACTTTTTATCTTCAAGCCGATGACGGAA 595
              ||||||||||||||||||||||| ||||||| |||||||||||||||||||||||||||
Db        694 CTCCGCACAGAGCTTCATAACCTCTTTCATGGGCTTTTTATCTTCAAGCCGATGACGGAA 753

Qy        596 AAATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGC 655
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        754 AAATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGC 813

Qy        656 CTACAAATTTGAGA-GAATCATCTCTAAGCAAAATGTCCT---ATCTGCAAATGA-GAAA 710
              ||||||||||||||| |||||||||||||||||||||||   |||||||||||| ||||
Db        814 CTACAAATTTGAGAGGAATCATCTCTAAGCAAAATGTCCTCAGATCTGCAAATGAGGAAA 873

Qy        711 TTCACAAGCGCACAGGAATTTTCTTGAAG-ATGGAGAAAGTGATGGCTTTTTAAGATGCC 769
              ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||
Db        874 TTCACAAGCGCACAGGAATTTTCTTGAAGTATGGAGAAAGTGATGGCTTTTTAAGATGCC 933

Qy        770 TCTCTCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGC 829
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        934 TCTCTCTTAACTCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGC 993

Qy        830 TTT-GGATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAG 888
              ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        994 TTTGGGATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAG 1053

Qy        889 CTGAGTATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCT 948
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1054 CTGAGTATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCT 1113

Qy        949 TCTTCTCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCT 1008
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1114 TCTTCTCTTGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCT 1173

Qy        1009 ACAAAAGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTA 1068
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1174 ACAAAAGTGAATCTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTA 1233

Qy        1069 ATAGACATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGC 1128
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1234 ATAGACATCTAAAATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGC 1293

Qy        1129 CTTAAGAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
               |||||||||||||||||||||||||||||||||||||||||||||
Db       1294 CTTAAGAAATCACTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1339
```

```
RESULT 22
BD233458
LOCUS       BD233458                969 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Human protein having hydrophobic domain and DNA encoding the same.
ACCESSION   BD233458
VERSION     BD233458.1  GI:33043228
KEYWORDS    JP 2002519016-A/4.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 969)
  AUTHORS   Kato,S. and Kimura,T.
  TITLE     Human protein having hydrophobic domain and DNA encoding the same
```

```
  JOURNAL   Patent: JP 2002519016-A 4 02-JUL-2002;
            SAGAMI CHEMICAL RESEARCH CENTER,PROTEGENE INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002519016-A/4
            PD   02-JUL-2002
            PF   18-JUN-1999 JP 2000557267
            PI   SEISHI KATO,TOMOKO KIMURA
            PC
            C12N15/09,C07K14/47,C12N1/15,C12N1/19,C12N5/10,C12N15/00,C12N5/ PC
             00
            CC   Human protein having hydrophobic domain and DNA encoding the
            CC             same
            FH   Key             Location/Qualifiers
            FT   source          1. .969
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .969
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"
ORIGIN

  Query Match             82.5%;  Score 969;  DB 6;  Length 969;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-224;
  Matches  969;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          70 ATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGCTG 129
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 ATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGCTG 60

Qy         130 CTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACTCG 189
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 CTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCATTTGACTCG 120

Qy         190 GTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACACC 249
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 GTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCCTTGCACACC 180

Qy         250 TACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTTGT 309
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 TACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTTTCAATTTGT 240

Qy         310 CAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCATGT 369
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         241 CAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAATCTGCATGT 300

Qy         370 ACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATCAG 429
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         301 ACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAGAATCAG 360

Qy         430 CTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACCTA 489
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         361 CTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAAATGCACCTA 420

Qy         490 CTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGAGC 549
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         421 CTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCCGCACAGAGC 480

Qy         550 TTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATTC 609
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         481 TTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATTC 540

Qy         610 CAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGAGA 669
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         541 CAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGAGA 600

Qy         670 GAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGAAT 729
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         601 GAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCGCACAGGAAT 660

Qy         730 TTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGTGG 789
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         661 TTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAACTCTGGGTGG 720

Qy         790 ATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAACT 849
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         721 ATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTGCAACT 780

Qy         850 GTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACTTG 909
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         781 GTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTATGGTGACTTG 840

Qy         910 GAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTAGA 969
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         841 GAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTGGTTGTTAGA 900

Qy         970 TCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTCAT 1029
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         901 TCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTCAT 960

Qy        1030 TCTGAAATT 1038
               |||||||||
Db         961 TCTGAAATT 969

Search completed: June 15, 2004, 05:14:15
Job time : 4881 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: June 15, 2004, 03:37:20 ; Search time 538 Seconds
(without alignments)
9270.232 Million cell updates/sec

Title: US-09-978-299A-329
Perfect score: 1174
Sequence: 1 cggacgcgtgggggaaaccc.....taaagttactcaaatctgtg 1174

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 210

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database : N_Geneseq_29Jan04:*
1: geneseqn1980s:*
2: geneseqn1990s:*
3: geneseqn2000s:*
4: geneseqn2001as:*
5: geneseqn2001bs:*
6: geneseqn2002s:*
7: geneseqn2003as:*
8: geneseqn2003bs:*
9: geneseqn2003cs:*
10: geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1174	100.0	1174	2	AAZ34171	Aaz34171 Human PRO
2	1174	100.0	1174	3	AAC78540	Aac78540 Human PRO
3	1174	100.0	1174	3	AAA77533	Aaa77533 Human PRO
4	1174	100.0	1174	4	AAS21379	Aas21379 Human cDN
5	1174	100.0	1174	4	AAC97400	Aac97400 Human ang
6	1174	100.0	1174	6	ABL88075	Abl88075 Human PRO
7	1174	100.0	1174	6	ABL95564	Abl95564 Human ang
8	1174	100.0	1174	7	ACD23988	Acd23988 Novel hum
9	1174	100.0	1174	7	ACD42704	Acd42704 Novel hum
10	1174	100.0	1174	7	ACA67129	Aca67129 cDNA enco
11	1174	100.0	1174	7	ACA63739	Aca63739 Novel hum
12	1174	100.0	1174	7	ACA03738	Aca03738 cDNA enco
13	1174	100.0	1174	7	ACA71903	Aca71903 Human sec
14	1174	100.0	1174	7	ABX89276	Abx89276 DNA encod
15	1174	100.0	1174	7	ABX92543	Abx92543 cDNA enco
16	1174	100.0	1174	7	ACD41930	Acd41930 Human sec
17	1174	100.0	1174	7	ACA66284	Aca66284 Human cDN
18	1174	100.0	1174	7	ACA04159	Aca04159 Human cDN
19	1174	100.0	1174	8	ADA45790	Ada45790 Novel hum
20	1174	100.0	1174	8	ADA76221	Ada76221 Human PRO
21	1174	100.0	1174	8	ADA18871	Ada18871 Human PRO
22	1174	100.0	1174	8	ADA61494	Ada61494 Homo sapi
23	1174	100.0	1174	8	ADB19279	Adb19279 Novel hum
24	1174	100.0	1174	8	ADB27820	Adb27820 cDNA enco
25	1174	100.0	1174	8	ADA86299	Ada86299 Novel hum
26	1174	100.0	1174	8	ADB15863	Adb15863 Human PRO
27	1174	100.0	1174	8	ADA47649	Ada47649 Human PRO
28	1174	100.0	1174	8	ADA67444	Ada67444 Human PRO
29	1174	100.0	1174	8	ADB30451	Adb30451 cDNA enco
30	1174	100.0	1174	8	ADA85747	Ada85747 Novel hum
31	1174	100.0	1174	8	ADA96959	Ada96959 Human PRO
32	1174	100.0	1174	8	ADA79263	Ada79263 Human PRO
33	1174	100.0	1174	8	ADA87402	Ada87402 Novel hum
34	1174	100.0	1174	8	ADB16604	Adb16604 Human PRO
35	1174	100.0	1174	8	ADA91696	Ada91696 Novel hum
36	1174	100.0	1174	8	ADB14759	Adb14759 Human PRO
37	1174	100.0	1174	8	ADA24868	Ada24868 Novel hum
38	1174	100.0	1174	8	ADB18720	Adb18720 Novel hum
39	1174	100.0	1174	8	ADA93935	Ada93935 Human PRO
40	1174	100.0	1174	8	ADB19831	Adb19831 Novel hum
41	1174	100.0	1174	8	ADB13143	Adb13143 Human PRO
42	1174	100.0	1174	8	ACD98559	Acd98559 Novel hum
43	1174	100.0	1174	8	ACD29885	Acd29885 Novel hum
44	1174	100.0	1174	8	ADA12529	Ada12529 Human cDN
45	1174	100.0	1174	8	ADA74397	Ada74397 Human PRO
46	1174	100.0	1174	8	ADB24630	Adb24630 Human PRO
47	1174	100.0	1174	8	ADA82154	Ada82154 Human PRO
48	1174	100.0	1174	8	ADA75117	Ada75117 Human PRO
49	1174	100.0	1174	8	ADA85195	Ada85195 Novel hum
50	1174	100.0	1174	8	ADA84643	Ada84643 Novel hum
51	1174	100.0	1174	8	ADB29899	Adb29899 cDNA enco
52	1174	100.0	1174	8	ADA80427	Ada80427 Human PRO
53	1174	100.0	1174	8	ADA75669	Ada75669 Human PRO
54	1174	100.0	1174	8	ADA46894	Ada46894 Human PRO
55	1174	100.0	1174	8	ADB25190	Adb25190 Human PRO
56	1174	100.0	1174	8	ADA93366	Ada93366 Human PRO
57	1174	100.0	1174	8	ADB26716	Adb26716 cDNA enco
58	1174	100.0	1174	8	ADB31003	Adb31003 cDNA enco
59	1174	100.0	1174	8	ADA60931	Ada60931 Homo sapi
60	1174	100.0	1174	8	ADB24078	Adb24078 Human PRO
61	1174	100.0	1174	8	ADA96407	Ada96407 Human PRO
62	1174	100.0	1174	8	ADA80979	Ada80979 Human PRO
63	1174	100.0	1174	8	ADA95855	Ada95855 Human PRO
64	1174	100.0	1174	8	ADB26164	Adb26164 cDNA enco
65	1174	100.0	1174	8	ADB21649	Adb21649 Novel hum
66	1174	100.0	1174	8	ACD29300	Acd29300 Novel hum
67	1174	100.0	1174	8	ADA77428	Ada77428 Human PRO
68	1174	100.0	1174	8	ADB18168	Adb18168 cDNA enco
69	1174	100.0	1174	8	ADA86851	Ada86851 Novel hum
70	1174	100.0	1174	8	ADA87954	Ada87954 Novel hum
71	1174	100.0	1174	8	ADA46342	Ada46342 Novel hum
72	1174	100.0	1174	8	ADB28372	Adb28372 cDNA enco
73	1174	100.0	1174	8	ADB28924	Adb28924 cDNA enco
74	1174	100.0	1174	8	ADA76876	Ada76876 Human PRO
75	1174	100.0	1174	8	ADA88506	Ada88506 Novel hum
76	1174	100.0	1174	8	ADA97511	Ada97511 Human PRO
77	1174	100.0	1174	8	ADB27268	Adb27268 cDNA enco
78	1174	100.0	1174	8	ADB22201	Adb22201 Novel hum
79	1174	100.0	1174	8	ADA66892	Ada66892 Human PRO
80	1174	100.0	1174	8	ADB22753	Adb22753 Human PRO
81	1174	100.0	1174	8	ADB23526	Adb23526 Human PRO
82	1174	100.0	1174	8	ADA92248	Ada92248 Novel hum
83	1174	100.0	1174	8	ADB15311	Adb15311 Human PRO
84	1174	100.0	1174	8	ADB38563	Adb38563 Novel hum
85	1174	100.0	1174	8	ADB38011	Adb38011 Novel hum
86	1174	100.0	1174	9	ADB66483	Adb66483 Novel hum
87	1174	100.0	1174	9	ADB89563	Adb89563 Human PRO
88	1174	100.0	1174	9	ADB90295	Adb90295 Human PRO
89	1174	100.0	1174	9	ADB39396	Adb39396 Novel hum
90	1174	100.0	1174	9	ADB73835	Adb73835 Human PRO
91	1174	100.0	1174	9	ADB47019	Adb47019 Novel hum
92	1174	100.0	1174	9	ADB86626	Adb86626 Human PRO
93	1174	100.0	1174	9	ADB76551	Adb76551 Human PRO
94	1174	100.0	1174	9	ADB77231	Adb77231 Novel hum
95	1174	100.0	1174	9	ADB34388	Adb34388 Human PRO
96	1174	100.0	1174	9	ADB35492	Adb35492 Human PRO

97	1174	100.0	1174	9	ADB33836	Adb33836 Human PRO
98	1174	100.0	1174	9	ADB34940	Adb34940 Human PRO
99	1174	100.0	1174	9	ADB36044	Adb36044 Human PRO
100	1174	100.0	1174	9	ADB46439	Adb46439 Novel hum
101	1174	100.0	1174	9	ADC43977	Adc43977 Human cDN
102	1174	100.0	1174	9	ADC61737	Adc61737 Human cDN
103	1174	100.0	1174	9	ADC63701	Adc63701 Human cDN
104	1174	100.0	1174	9	ADC66801	Adc66801 Human cDN
105	1174	100.0	1174	9	ADC68925	Adc68925 Human cDN
106	1174	100.0	1174	9	ADC62985	Adc62985 Human cDN
107	1174	100.0	1174	9	ADC68050	Adc68050 Human cDN
108	1174	100.0	1174	9	ADC41370	Adc41370 Human cDN
109	1174	100.0	1174	9	ADC67425	Adc67425 Human cDN
110	1174	100.0	1174	9	ADC62361	Adc62361 Human cDN
111	1174	100.0	1174	9	ADC41994	Adc41994 Human cDN
112	1174	100.0	1174	9	ADC50312	Adc50312 Novel hum
113	1174	100.0	1174	9	ADC71859	Adc71859 Novel hum
114	1174	100.0	1174	9	ADC59838	Adc59838 Novel hum
115	1174	100.0	1174	9	ADC52845	Adc52845 Novel hum
116	1174	100.0	1174	9	ADC57199	Adc57199 Novel hum
117	1174	100.0	1174	9	ADC60390	Adc60390 Novel hum
118	1174	100.0	1174	9	ADC50865	Adc50865 Novel hum
119	1174	100.0	1174	9	ADC65392	Adc65392 Human PRO
120	1174	100.0	1174	9	ADC54490	Adc54490 Novel hum
121	1174	100.0	1174	9	ADC53451	Adc53451 Novel hum
122	1174	100.0	1174	9	ADC58974	Adc58974 Novel hum
123	1174	100.0	1174	9	ADC55852	Adc55852 Novel hum
124	1174	100.0	1174	9	ADC58422	Adc58422 Novel hum
125	1174	100.0	1174	9	ADD03096	Add03096 Novel hum
126	1174	100.0	1174	9	ADC90088	Adc90088 Novel hum
127	1174	100.0	1174	9	ADC69507	Adc69507 cDNA enco
128	1174	100.0	1174	9	ADC48396	Adc48396 Human PRO
129	1174	100.0	1174	9	ADD09925	Add09925 Human PRO
130	1174	100.0	1174	9	ADD04500	Add04500 Novel hum
131	1174	100.0	1174	9	ADC80456	Adc80456 Novel hum
132	1174	100.0	1174	9	ADD10963	Add10963 Human PRO
133	1174	100.0	1174	9	ADD10296	Add10296 Human sec
134	1174	100.0	1174	9	ADC47844	Adc47844 Human PRO
135	1174	100.0	1174	9	ADC79904	Adc79904 Novel hum
136	1174	100.0	1174	9	ADD11256	Add11256 Human sec
137	1174	100.0	1174	9	ADD09373	Add09373 Human PRO
138	1174	100.0	1174	9	ADD41086	Add41086 Novel hum
139	1174	100.0	1174	9	ADD52225	Add52225 cDNA enco
140	1174	100.0	1174	9	ADD52965	Add52965 cDNA enco
141	1174	100.0	1174	9	ADD53517	Add53517 Novel hum
142	1174	100.0	1174	9	ADD37049	Add37049 Human sec
143	1174	100.0	1174	9	ADD51673	Add51673 cDNA enco
144	1174	100.0	1174	9	ADD02472	Add02472 Human PRO
145	1174	100.0	1174	9	ADD01906	Add01906 Human PRO
146	1174	100.0	1174	9	ADD54088	Add54088 Novel hum
147	1174	100.0	1174	9	ADE49363	Ade49363 Human cDN
148	1174	100.0	1174	9	ADD92405	Add92405 Human PRO
149	1174	100.0	1174	9	ADD91301	Add91301 Human PRO
150	1174	100.0	1174	9	ADE03915	Ade03915 Human PRO
151	1174	100.0	1174	9	ADE32212	Ade32212 Novel hum
152	1174	100.0	1174	9	ADE22144	Ade22144 cDNA enco
153	1174	100.0	1174	9	ADD79368	Add79368 cDNA enco
154	1174	100.0	1174	9	ADE35417	Ade35417 Human cDN
155	1174	100.0	1174	9	ADE16531	Ade16531 Human cDN
156	1174	100.0	1174	9	ADD73146	Add73146 Human cDN
157	1174	100.0	1174	9	ADE41904	Ade41904 Human PRO
158	1174	100.0	1174	9	ADE17721	Ade17721 Human PRO
159	1174	100.0	1174	9	ADD91853	Add91853 Human PRO
160	1174	100.0	1174	9	ADE33316	Ade33316 Novel hum
161	1174	100.0	1174	9	ADE33868	Ade33868 Novel hum
162	1174	100.0	1174	9	ADD79920	Add79920 cDNA enco
163	1174	100.0	1174	9	ADD92957	Add92957 Human PRO
164	1174	100.0	1174	9	ADD72504	Add72504 Human cDN
165	1174	100.0	1174	9	ADE19377	Ade19377 Human PRO
166	1174	100.0	1174	9	ADE18825	Ade18825 Human PRO
167	1174	100.0	1174	9	ADE43021	Ade43021 Human PRO
168	1174	100.0	1174	9	ADD95810	Add95810 Human PRO
169	1174	100.0	1174	9	ADE22696	Ade22696 cDNA enco
170	1174	100.0	1174	9	ADD78814	Add78814 cDNA enco
171	1174	100.0	1174	9	ADE32764	Ade32764 Novel hum
172	1174	100.0	1174	9	ADE42456	Ade42456 Human PRO
173	1174	100.0	1174	9	ADE17155	Ade17155 Human cDN
174	1174	100.0	1174	9	ADD80472	Add80472 cDNA enco
175	1174	100.0	1174	9	ADD89500	Add89500 Human PRO
176	1174	100.0	1174	9	ADE40784	Ade40784 Human PRO
177	1174	100.0	1174	9	ADE04583	Ade04583 Human PRO
178	1174	100.0	1174	10	ADC81008	Adc81008 Novel hum
179	1174	100.0	1174	10	ADD76456	Add76456 Human PRO
180	1174	100.0	1174	10	ADD87820	Add87820 Human PRO
181	1174	100.0	1174	10	ADD86224	Add86224 Human PRO
182	1174	100.0	1174	10	ADE75672	Ade75672 Human PRO
183	1174	100.0	1174	10	ADE48663	Ade48663 Human cDN
184	1174	100.0	1174	10	ADE41257	Ade41257 Human sec
185	1174	100.0	1174	10	ADE23248	Ade23248 cDNA enco
186	1174	100.0	1174	10	ADE23800	Ade23800 cDNA enco
187	1174	100.0	1174	10	ADE24443	Ade24443 cDNA enco
188	1174	100.0	1174	10	ADD87268	Add87268 Human PRO
189	1174	100.0	1174	10	ADE89134	Ade89134 Human PRO
190	1174	100.0	1174	10	ADE18273	Ade18273 Human PRO
191	1174	100.0	1174	10	ADE88582	Ade88582 Human PRO
192	1174	100.0	1174	10	ADE89764	Ade89764 Human cDN
193	1163.8	99.1	1634	4	AAK94533	Aak94533 Human ful
194	1163.8	99.1	1696	9	ADC37344	Adc37344 Nuclear f
195	1163.8	99.1	1704	3	AAZ56760	Aaz56760 Human tra
196	1151.8	98.1	1695	2	AAV59792	Aav59792 Human sec
197	1151.8	98.1	1695	6	ABS73786	Abs73786 Human cDN
198	1151.8	98.1	1695	8	ACD82929	Acd82929 cDNA sequ
199	1121	95.5	1121	3	AAZ90051	Aaz90051 Hydrophob
200	1118	95.2	1457	5	AAF93855	Aaf93855 Human cDN
201	1106	94.2	1138	2	AAX82075	Aax82075 Human CBC
202	1106	94.2	1138	7	ABZ72012	Abz72012 Human unk
203	1106	94.2	1138	7	ABZ75896	Abz75896 Heart dis
204	1105	94.1	1466	9	ADC37346	Adc37346 Nuclear f
205	1103	94.0	1109	6	ABK35662	Abk35662 cDNA sequ
206	1097	93.4	1472	2	AAX35556	Aax35556 Secreted
207	1049	89.4	1756	2	AAV59667	Aav59667 Human sec
208	1049	89.4	1816	6	ABS73654	Abs73654 Human cDN
209	1049	89.4	1816	8	ACD82797	Acd82797 cDNA sequ
210	969	82.5	969	3	AAZ90041	Aaz90041 Hydrophob

ALIGNMENTS

RESULT 1
AAZ34171
ID AAZ34171 standard; cDNA; 1174 BP.
XX
AC AAZ34171;
XX
DT 07-DEC-1999 (first entry)
XX
DE Human PRO195 nucleotide sequence.
XX
KW Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;
KW probe; blood coagulation disorder; cancer; cellular adhesion disorder;
KW secreted protein; transmembrane protein; ss.
XX
OS Homo sapiens.
XX
PN WO9946281-A2.
XX
PD 16-SEP-1999.
XX
PF 08-MAR-1999; 99WO-US005028.
XX
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082767P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
XX
PA (GETH) GENENTECH INC.
XX
PI Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;
XX
DR WPI; 1999-551358/46.
DR P-PSDB; AAY41733.
XX
PT New secreted and transmembrane polypeptides and their polynucleotides,
PT useful for treating blood coagulation disorders, cancers and cellular
PT adhesion disorders.
XX
PS Claim 2; Fig 131; 530pp; English.
XX
CC The present invention describes secreted and transmembrane polypeptides
CC and their polynucleotides. The nucleotide sequences are useful as sources
CC of probes, primers, for chromosome mapping, and for generation of
CC antisense sequences. They can also be used to create transgenic animals.
CC The proteins can be used to treat a variety of diseases and disorders,
CC depending on their function. Diseases that may be treated include blood
CC coagulation disorders, cancers and cellular adhesion disorders. They may
CC also be used to raise antibodies. AAZ33891 to AAZ34338, and AAY41685 to
CC AAY41774 represent polynucleotide and polypeptide sequence given in the
CC exemplification of the present invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 2; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
```

```
Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
            |||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 2
AAC78540
ID AAC78540 standard; cDNA; 1174 BP.
XX
AC AAC78540;
XX
DT 08-FEB-2001 (first entry)
XX
DE Human PRO195 (UNQ169) nucleotide sequence SEQ ID NO:329.
XX
KW Human; secreted protein; transmembrane protein; PRO; EST; cytostatic;
KW expressed sequence tag; detection; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200053756-A2.
XX
PD 14-SEP-2000.
XX
PF 18-FEB-2000; 2000WO-US004341.
XX
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0145698P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2000-611443/58.
DR P-PSDB; AAB44289.
XX
PT Novel PRO polypeptides and polynucleotides used in detection methods, to
PT target bioactive molecules to specific cells, and to modulate cellular
PT activities.
XX
PS Claim 2; Fig 131; 636pp; English.
XX
CC AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence
CC tag) sequences which encode secreted or transmembrane PRO polypeptides.
CC The PRO polynucleotides and polypeptides have cytostatic activity. The
CC polynucleotides and polypeptides can be used for detecting the presence
CC of PRO polypeptides in samples, for linking bioactive molecules to cells
CC and for modulating biological activities of cells, using the polypeptides
CC for specific targeting. The polypeptide targeting can be used to kill the
CC target cells, e.g. for the treatment of cancers. The polypeptide pairs
CC provide specific targeting of bioactive molecules to cells. AAC78600 to
CC AAC78987 represent PCR primers and probes used in the isolation of the
CC PRO polynucleotide sequences
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 3; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 3
AAA77533
ID AAA77533 standard; cDNA; 1174 BP.
XX
AC AAA77533;
XX
DT 07-NOV-2000 (first entry)
XX
DE Human PRO195 cDNA sequence SEQ ID NO:30.
XX
KW Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;
KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;
KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;
KW cytostatic; gene therapy; vaccine; ss.
XX
OS Homo sapiens.
XX
PN WO200032221-A2.
XX
PD 08-JUN-2000.
XX
PF 30-NOV-1999; 99WO-US028313.
XX
PR 01-DEC-1998; 98WO-US025108.
PR 16-DEC-1998; 98US-0112850P.
PR 12-JAN-1999; 99US-0115554P.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-OCT-1999; 99US-0162506P.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ;
PI Goddard A, Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF;
PI Smith V, Watanabe CK, Williams PM, Wood WI;
XX
DR WPI; 2000-412154/35.
DR P-PSDB; AAB24394.
XX
PT Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing
PT and treating diagnosing a cardiovascular, endothelial or angiogenic
PT disorders in mammals.
XX
PS Claim 61; Fig 13; 315pp; English.
XX
CC The present invention describes nucleic acids encoding PRO polypeptides
CC useful for preventing, diagnosing and treating diagnosing a
CC cardiovascular, endothelial or angiogenic disorder in mammals by
CC modulating cell proliferation, angiogenesis and cardiovascularisation,
CC and for identifying agonists and antagonists of these processes. The
CC nucleic acids and the proteins they encode may be used in the prevention,
CC treatment and diagnosis of diseases associated with inappropriate PRO
CC expression such as cardiovascular, endothelial or angiogenic disorders in
CC mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For
CC example, the nucleic acids (NCs) and vectors containing them and the PRO
CC polypeptide may be used to treat disorders associated with decreased PRO
CC expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent
CC nucleotide and protein sequences used in the exemplification of the
CC present invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 3; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
```

```
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 4

```
AAS21379
ID   AAS21379 standard; cDNA; 1174 BP.
XX
AC   AAS21379;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human cDNA sequence encoding for PRO195 polypeptide.
XX
KW   Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW   prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
KW   ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
KW   A-peptide; factor VIIA; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200140466-A2.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US032678.
XX
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   09-DEC-1999;   99US-0170262P.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005841.
PR   03-MAR-2000; 2000US-0187202P.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   05-JUN-2000; 2000US-0209832P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-408281/43.
DR   P-PSDB; AAU12307.
XX
PT   Isolated , secretory and transmembrane PRO polypeptide used to detect
PT   other PRO polypeptides, link bioactive molecules to cells expressing PRO
```

PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
PT breast, prostate, cervical.
XX
PS Claim 3; Fig 271; 813pp; English.
XX
CC AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO
CC polypeptides. The PRO polypeptides are useful to detect other PRO
CC polypeptides, to link bioactive molecules to cells expressing PRO
CC polypeptides, to modulate biological activities of cells expressing PRO
CC polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample. Some
CC of the 275 sequences are also useful to stimulate the release of tumour
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
CC differentiation of chondrocytes, the proliferation or gene expression in
CC pericyte cells, the release of proteoglycans from cartilage, the
CC proliferation of inner ear utricular supporting cells or of T-
CC lymphocytes, the release of a cytokine from peripheral blood monocytes
CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
CC VIIA. The PRO polypeptides can be used in assays to identify molecules
CC involved in binding interactions. The polynucleotides encoding PRO
CC polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 4; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 5
AAC97400
ID AAC97400 standard; cDNA; 1174 BP.
XX
AC AAC97400;
XX
DT 28-FEB-2001 (first entry)
XX
DE Human angiogenesis-associated protein PRO195 cDNA, SEQ ID NO:45.
XX
KW Human; angiogenesis-associated protein; PRO; endothelial cell growth;
KW cardiac hypertrophy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; atherosclerosis; osteoporosis; hypertension;
KW myocardial infarction; diabetic retinopathy; rheumatoid arthritis;
KW Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;
KW Alzheimer's disease; Huntington's disease; stroke; drug screening;
KW gene therapy; transgenic animal; ss.
XX
OS Homo sapiens.
XX
PN WO200053753-A2.
XX
PD 14-SEP-2000.
XX
PF 05-JAN-2000; 2000WO-US000219.
XX
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.

PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Kuo SS, Mark MR, Marsters SA;
PI Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;
XX
DR WPI; 2001-090793/10.
DR P-PSDB; AAB53073.
XX
PT New isolated nucleic acid for producing a PRO polypeptide, analyzing
PT genetic disorders and treating cardiovascular, endothelial or angiogenic
PT disorders, such as atherosclerosis, wounds or cancer.
XX
PS Claim 58; Fig 19; 293pp; English.
XX
CC The invention relates to novel human angiogenesis-associated proteins
CC designated PRO proteins (AAB53064-B53097), and to nucleic acids encoding
CC PRO proteins. The invention also relates to vectors and host cells
CC comprising a PRO nucleic acid, the recombinant production of a PRO
CC protein, PRO antibodies specific for a PRO protein, fusion proteins
CC comprising a PRO protein, agonists or antagonists of a PRO protein, and
CC compounds which inhibit the expression of a PRO gene. The invention
CC additionally encompasses methods of identifying modulators of PRO
CC expression or activity; diagnosing a cardiovascular, endothelial or
CC angiogenic disorder, or a susceptibility to such a disorder by detecting
CC mutations in a PRO gene, or the expression level of a PRO gene within a
CC particular tissue; treating a cardiovascular, endothelial or angiogenic
CC disorder via the administration of a PRO protein, PRO nucleic acid, or
CC PRO agonist or antagonist; a retroviral gene therapy vector comprising a
CC PRO nucleic acid; and methods of inhibiting or stimulating endothelial
CC cell growth, cardiac hypertrophy or PRO-induced angiogenesis via the
CC administration of a PRO protein, or an agonist or antagonist thereof. PRO
CC nucleic acids, PRO proteins, antibodies against PRO proteins, PRO
CC agonists and PRO antagonists may be used as therapeutic agents to treat
CC cardiovascular, endothelial or angiogenic disorders, such as
CC atherosclerosis, osteoporosis, myocardial infarction, hypertension,
CC diabetic retinopathy, rheumatoid arthritis, Crohn's disease, psoriasis,
CC endometriosis, ulcers, wounds, cancer, Alzheimer's disease, Huntington's
CC disease, or stroke. PRO nucleic acids are additionally useful in the
CC recombinant production of PRO proteins, as hybridisation probes to screen
CC libraries to isolate cDNAs with sequence identity to PRO proteins, to map
CC genes encoding PRO proteins, to analyse genetic disorders, and in gene
CC therapy. PRO nucleic acids can also be used to produce transgenic animals
CC useful for the development and screening of potential therapeutic agents.
CC The present sequence represents a cDNA encoding a PRO protein of the
CC invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 4; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 6
ABL88075

ID ABL88075 standard; cDNA; 1174 BP.
XX
AC ABL88075;
XX
DT 16-MAY-2002 (first entry)
XX
DE Human PRO195 cDNA sequence SEQ ID NO:7.
XX
KW Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW age-related macular degeneration; arterial restenosis; angina;
KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200200690-A2.
XX
PD 03-JAN-2002.
XX
PF 20-JUN-2001; 2001WO-US019692.
XX
PR 23-JUN-2000; 2000US-0213637P.
PR 20-JUL-2000; 2000US-0219556P.
PR 25-JUL-2000; 2000US-0220624P.
PR 25-JUL-2000; 2000US-0220664P.
PR 28-JUL-2000; 2000WO-US020710.
PR 02-AUG-2000; 2000US-0222695P.
PR 17-AUG-2000; 2000US-00643657.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 24-OCT-2000; 2000US-0242922P.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 22-JAN-2001; 2001US-00767609.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 30-MAY-2001; 2001US-00870574.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-090516/12.
DR P-PSDB; ABB84820.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
PS Claim 2; Fig 7; 565pp; English.
XX
CC ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,
CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal, e.g.
CC cardiac hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The PRO polynucleotides have applications in molecular biology,
CC including use as hybridisation probes, and in chromosome and gene
CC mapping. ABL88259 to ABL88267 represent primers and probes used in the
CC exemplification of the present invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
```

```
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
                    |||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 7
ABL95564
ID ABL95564 standard; cDNA; 1174 BP.
XX
AC ABL95564;
XX
DT 19-JUL-2002 (first entry)
XX
DE Human angiogenesis related cDNA PRO195 SEQ ID NO: 7.
XX
KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200208284-A2.
XX
PD 31-JAN-2002.
XX
PF 09-JUL-2001; 2001WO-US021735.
XX
PR 20-JUL-2000; 2000US-0219556P.
PR 25-JUL-2000; 2000US-0220624P.
PR 25-JUL-2000; 2000US-0220664P.
PR 28-JUL-2000; 2000WO-US020710.
PR 02-AUG-2000; 2000US-0222695P.
PR 17-AUG-2000; 2000US-00643657.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 24-OCT-2000; 2000US-0242922P.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 22-JAN-2001; 2001US-00767609.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 30-MAY-2001; 2001US-00870574.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
XX
PA (GETH) GENENTECH INC.
PA (BAKE/) BAKER K P.
PA (FERR/) FERRARA N.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (MARS/) MARSTERS S A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (STEP/) STEPHAN J F.
PA (WATA/) WATANABE C K.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-171999/22.
DR P-PSDB; ABB95426.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
PS Claim 1; Fig 7; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a coding sequence of the invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 6; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 8
ACD23988
```

```
ID   ACD23988 standard; cDNA; 1174 BP.
XX
AC   ACD23988;
XX
DT   26-AUG-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW   antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW   antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW   TNF-alpha release; cell proliferation; cell differentiation;
KW   gene expression modulator; proteoglycan release; cytokine release;
KW   tumour; inflammatory disease; organ failure; atherosclerosis;
KW   cardiac injury; infertility; birth defect; premature aging; AIDS;
KW   acquired immunodeficiency syndrome; cancer; diabetic complication;
KW   chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW   bioreactor; tissue typing; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003032156-A1.
XX
PD   13-FEB-2003.
XX
PF   06-MAY-2002; 2002US-00140474.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
```

PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-341980/32.
DR P-PSDB; ABO17751.
XX
PT New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, axquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This sequence encodes a novel human secreted and transmembrane PRO
CC polypeptide
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
```

```
Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
            |||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 9
ACD42704
ID ACD42704 standard; cDNA; 1174 BP.
XX
AC ACD42704;
XX
DT 09-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; virucide; gene therapy;
KW cell death; growth induction cascade; blood coagulation cascade;
KW viral infection; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003050239-A1.
XX
PD 13-MAR-2003.
XX
PF 15-OCT-2001; 2001US-00978191.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.

PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
```

```
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 10
ACA67129
ID   ACA67129 standard; cDNA; 1174 BP.
XX
AC   ACA67129;
XX
DT   23-JUN-2003 (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW   bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW   sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW   hearing loss; coagulation disorder; stroke; heart attack; cardiant;
KW   antidiabetic; anorectic; vulnerary; antiarthritic; osteopathic;
KW   antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003004311-A1.
XX
PD   02-JAN-2003.
XX
PF   19-DEC-2001; 2001US-00028072.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
PR   17-SEP-1997;   97US-0059184P.
PR   18-SEP-1997;   97US-0059263P.
PR   19-SEP-1997;   97US-0059352P.
PR   19-SEP-1997;   97US-0059588P.
PR   24-SEP-1997;   97US-0059836P.
PR   17-OCT-1997;   97US-0062250P.
PR   17-OCT-1997;   97US-0062285P.
PR   17-OCT-1997;   97US-0062287P.
PR   17-OCT-1997;   97US-0063755P.
PR   24-OCT-1997;   97US-0062814P.
PR   24-OCT-1997;   97US-0062816P.
PR   24-OCT-1997;   97US-0063045P.
PR   24-OCT-1997;   97US-0063082P.
PR   24-OCT-1997;   97US-0063127P.
PR   27-OCT-1997;   97US-0063327P.
PR   27-OCT-1997;   97US-0063329P.
PR   28-OCT-1997;   97US-0063550P.
PR   28-OCT-1997;   97US-0063561P.
PR   29-OCT-1997;   97US-0063704P.
PR   29-OCT-1997;   97US-0063733P.
PR   29-OCT-1997;   97US-0063735P.
PR   29-OCT-1997;   97US-0063738P.
PR   03-NOV-1997;   97US-0064248P.
PR   07-NOV-1997;   97US-0064809P.
PR   12-NOV-1997;   97US-0065186P.
PR   17-NOV-1997;   97US-0065846P.
PR   21-NOV-1997;   97US-0066364P.
PR   24-NOV-1997;   97US-0066453P.
PR   24-NOV-1997;   97US-0066511P.
PR   24-NOV-1997;   97US-0066770P.
PR   11-DEC-1997;   97US-0069212P.
PR   11-DEC-1997;   97US-0069278P.
PR   11-DEC-1997;   97US-0069334P.
PR   16-DEC-1997;   97US-0069694P.
PR   23-JAN-1998;   98US-0072320P.
PR   04-FEB-1998;   98US-0073612P.
PR   09-FEB-1998;   98US-0074086P.
PR   09-FEB-1998;   98US-0074092P.
PR   12-MAR-1998;   98US-0077791P.
PR   20-MAR-1998;   98US-0078910P.
PR   25-MAR-1998;   98US-0079294P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079728P.
PR   31-MAR-1998;   98US-0080165P.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-352836/33.
DR P-PSDB; ABU81005.
XX
PT New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT heart attack.
XX
PS Claim 2; Fig 271; 643pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of diabetes, bone and/or cartilage disorders
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells, tissues or
CC serum, and for affinity purification of PRO from recombinant cell culture
CC or natural sources. ACA66994-ACA67268 represent cDNA sequences encoding
CC the human PRO polypeptides of the invention. Note: The sequence data for
CC this patent was obtained in electronic format directly from the USPTO web
CC site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 11
ACA63739
ID ACA63739 standard; cDNA; 1174 BP.
XX
AC ACA63739;
XX
DT 16-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; inflammatory disease; organ failure;
KW atherosclerosis; cardiac injury; infertility; birth defect;
KW premature aging; AIDS; cancer; diabetic complication; chromosome mapping;
KW gene mapping; pharmaceutical; diagnostic; biosensor; bioreactor;
KW tissue typing; gene; ss.
XX

OS Homo sapiens.
XX
PN US2002192706-A1.
XX
PD 19-DEC-2002.
XX
PF 24-OCT-2001; 2001US-00999832.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-328860/31.
DR P-PSDB; ABU72241.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 131; 453pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC is at least 80 % sequence identity to, or the full-length coding sequence
CC of, any of 118 300-2100 nucleotide sequences, which encodes its
CC corresponding PRO polypeptide selected from 118 100-700 amino acid
CC sequences, all given in the specification. The nucleic acids and
CC polypeptides are useful for treating inflammatory diseases, organ
CC failure, atherosclerosis, cardiac injury, infertility, birth defects,
CC premature aging, AIDS, cancer, or diabetic complications. The nucleic
CC acids are useful as hybridisation probes, in chromosome and gene mapping,
CC and in generating antisense RNA or DNA. The polypeptides are useful as
CC pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful
CC in tissue typing. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy 61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

```
Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 12
ACA03738
ID   ACA03738 standard; cDNA; 1174 BP.
XX
AC   ACA03738;
XX
DT   23-MAY-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW   differentiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   US2003036180-A1.
XX
PD   20-FEB-2003.
XX
PF   09-MAY-2002; 2002US-00143114.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
```

PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332040/31.
DR P-PSDB; ABU66705.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue
PT typing, and in chromosome identification.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The PRO polypeptides are useful for
CC for stimulating the release of tumour necrosis factor (TNF)-alpha from
CC human blood, for stimulating the proliferation or differentiation of
CC chondrocytes, and detecting the presence of tumours. The polynucleotide
CC sequences encoding PRO polypeptides are useful as hybridisation probes,
CC in chromosome and gene mapping, in the generation of antisense RNA and
CC DNA, in the preparation of PRO polypeptides, for generating transgenic
CC animals or knockout animals, for the genetic analysis of individuals with
CC genetic disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs
CC encoding the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
```

```
Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 13
ACA71903
ID ACA71903 standard; cDNA; 1174 BP.
XX
AC ACA71903;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human secreted and transmembrane polypeptide PRO195 cDNA.
XX
KW Human; ss; gene; thrombolytic agent; interferon; interleukin; cytokine;
KW erythropoietin; colony stimulating factor; cancer; colorectal carcinoma;
KW apoptosis related condition; AIDS; amyotrophic lateral sclerosis;
KW inflammatory disease; asthma; atherosclerosis; neurodegenerative disease;
KW gastrointestinal disorder; Alzheimer's disease; Parkinson's disease;
KW hypertension; myocardial ischaemia; kidney disease; carcinogenesis;
KW glomerulonephritis; lung disease; pulmonary hypertension; preeclampsia;
KW bronchial asthma; gastric ulcer; renal failure; cardiovascular disease;
KW inflammatory bowel disease; reproductive disorder; premature labour.
XX
OS Homo sapiens.
XX
PN US2002177553-A1.
XX
PD 28-NOV-2002.
XX
PF 15-OCT-2001; 2001US-00978192.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX
DR WPI; 2003-328499/31.
DR P-PSDB; ABU84921.
XX
PT New isolated PRO polypeptides e.g. PRO213, PRO274 and PRO300, for use as
PT pharmaceuticals, diagnostics, biosensors and bioreactors, for identifying
PT modulators of receptor-ligand interactions.
XX
PS Claim 2; SEQ ID NO 329; 55pp; English.
XX
CC The invention relates to an isolated secreted and transmembrane
CC polypeptide, designated as PRO polypeptide. The PRO polypeptide is useful
CC in PRO polypeptide detection methods. The PRO polypeptide is useful for
CC linking a bioactive molecule to a cell. The PRO polypeptide or an
CC antibody against it is useful for modulating a biological activity of a
CC cell. The PRO polypeptide is useful in industrial applications including
CC pharmaceuticals, diagnostics, biosensors and bioreactors. The PRO
CC polypeptide is also useful as a thrombolytic agent, interferon,
CC interleukin, erythropoietin, colony stimulating factor and other
CC cytokines. The PRO polypeptide is useful for treating disease such as
CC cancer e.g. colorectal carcinoma; apoptosis related conditions e.g. AIDS,
CC amyotrophic lateral sclerosis; inflammatory disease e.g. asthma,
CC atherosclerosis; neurodegenerative disease e.g. Alzheimer's disease,
CC Parkinson's disease; cardiovascular disease e.g. hypertension and
CC myocardial ischaemia; kidney disease e.g. renal failure and
CC glomerulonephritis; lung disease e.g. pulmonary hypertension, bronchial
CC asthma; gastrointestinal disorders e.g. gastric ulcer and inflammatory
CC bowel disease; reproductive disorders e.g. premature labour and
CC preeclampsia; carcinogenesis. The present sequence represents a cDNA
CC encoding a PRO polypeptide of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20020177553
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 14
ABX89276
ID ABX89276 standard; cDNA; 1174 BP.
XX
AC ABX89276;
XX
DT 13-MAY-2003 (first entry)
XX
DE DNA encoding novel secreted and transmembrane protein PRO195.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003017563-A1.
XX

PD 23-JAN-2003.
XX
PF 07-MAY-2002; 2002US-00140808.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR P-PSDB; ABU59786.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are

```
CC   thus useful for treating sports injuries, and arthritis. This sequence
CC   encodes a novel human PRO protein
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 7;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 15
ABX92543
ID   ABX92543 standard; cDNA; 1174 BP.
XX
AC   ABX92543;
XX
DT   08-MAY-2003  (first entry)
XX
DE   cDNA encoding human PRO195 polypeptide.
XX
KW   Human; PRO polypeptide; secreted and transmembrane protein;
KW   immune disorder; diabetes; hyper-insulinaemia; hypo-insulinaemia;
KW   cardiac insufficiency; nervous system disorder; kidney disorder;
KW   bone disorder; cartilage disorder; arthritis; tumour; wound healing;
KW   genetic disorder; cytostatic; antidiabetic; antiinflammatory;
KW   antiarthritic; anti-tumour; vulnerary; antianaemic; dermatological;
KW   cardiant; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2002169284-A1.
XX
PD   14-NOV-2002.
XX
PF   16-OCT-2001; 2001US-00978697.
XX
PR   26-MAY-1981;   81US-00267213.
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   26-JUN-1998;   98US-00105413.
PR   07-OCT-1998;   98US-00168978.
PR   07-OCT-1998;   98WO-US021141.
PR   02-NOV-1998;   98US-00184216.
PR   06-NOV-1998;   98US-00187368.
```

PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton D;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-288163/28.
DR P-PSDB; ABU61119.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating cancer, kidney diseases, bone,
PT cartilage disorders and immune deficiencies.

XX
PS Claim 2; Fig 131; 459pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The bioactive molecule maybe a
CC toxin, radiolabel or antibody, and causes apoptosis or death of the cell.
CC The PRO polypeptides are useful for treating immune disorders, diabetes
CC or hyper- or hypo-insulinaemia, cardiac insufficiency, nervous system
CC disorders, kidney disorders, bone and cartilage disorders or arthritis,
CC tumours, and wound healing. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and gene
CC mapping, in the generation of antisense RNA and DNA, in the preparation
CC of PRO polypeptides, for generating transgenic animals or knockout
CC animals, for the genetic analysis of individuals with genetic disorders,
CC and in gene therapy. The present sequence encodes a human PRO polypeptide
CC of the invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
```

```
Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
            |||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 16
ACD41930
ID ACD41930 standard; cDNA; 1174 BP.
XX
AC ACD41930;
XX
DT 05-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #136.
XX
KW Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;
KW cytostatic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;
KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell; A-peptide; factor VIIA.
XX
OS Homo sapiens.
XX
PN US2003036179-A1.
XX
PD 20-FEB-2003.
XX
PF 10-MAY-2002; 2002US-00142431.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-466355/44.
DR P-PSDB; ABO24976.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising at least 80%
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC extracellular domain (with or without its associated signal peptide),
CC which comprises any of the 275 120-850 residue amino acid sequences,
CC given in the specification; (b) comprising any of the 275 300-3500
CC nucleotide sequences, given in the specification; or (c) comprising the
CC full-length coding sequence of the nucleotide sequences given in the
CC specification, or of the DNA deposited under any of the American Type
CC Culture Collection (ATCC) Accession Numbers listed in the specification.
CC Also included are a vector comprising the novel nucleic acid, a host cell
CC comprising the vector, producing a PRO polypeptide, the isolated PRO
CC polypeptides detailed above, a chimaeric molecule comprising the PRO
CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC antibody, detecting a PRO polypeptide in a sample suspected of containing
CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulating at least one biological activity of a cell
CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC modulating the uptake of glucose or FFA by skeletal muscle cells or
CC adipocyte cells, stimulating the proliferation or differentiation of
CC chondrocyte cells (or proliferation of or gene expression in pericyte
CC cells), stimulating the proliferation of inner ear utricular supporting
CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC cells, detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences given
CC in the specification. The polynucleotide is useful in molecular biology,
CC including uses as hybridisation probes, in chromosome and gene mapping,
CC in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptide or the
CC antibody is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The present sequence encodes a PRO polypeptide
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
```

```
Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 17
ACA66284
ID   ACA66284 standard; cDNA; 1174 BP.
XX
AC   ACA66284;
XX
DT   24-JUN-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   malignancy; cancer; ovarian cancer; colorectal cancer; sarcoma;
KW   leukaemia; lymphoma; inflammatory disease; necrosis; atherosclerosis;
KW   infertility; premature aging; psoriasis; inflammatory disease;
KW   renal disease; arthritis; immune-mediated alopecia; stroke; encephalitis;
KW   hepatitis; multiple sclerosis; gene therapy.
XX
OS   Homo sapiens.
XX
PN   US2003004102-A1.
XX
PD   02-JAN-2003.
XX
PF   15-OCT-2001; 2001US-00978189.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   26-JUN-1998;   98US-00105413.
PR   07-OCT-1998;   98US-00168978.
PR   07-OCT-1998;   98WO-US021141.
PR   02-NOV-1998;   98US-00184216.
PR   06-NOV-1998;   98US-00187368.
PR   20-NOV-1998;   98WO-US024855.
PR   07-DEC-1998;   98US-00202054.
PR   22-DEC-1998;   98US-00218517.
PR   05-JAN-1999;   99WO-US000106.
PR   05-MAR-1999;   99US-00254465.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99US-00265686.
PR   10-MAR-1999;   99WO-US005190.
PR   12-MAR-1999;   99US-00267213.
PR   12-APR-1999;   99US-00284291.
PR   14-MAY-1999;   99US-00311832.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   25-AUG-1999;   99US-00380138.
PR   25-AUG-1999;   99US-00380142.
PR   30-NOV-1999;   99WO-US028313.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000US-00709238.
PR   10-NOV-2000; 2000WO-US030873.
PR   27-NOV-2000; 2000US-00723749.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001WO-US006520.
PR   22-MAR-2001; 2001US-00816744.
PR   22-MAR-2001; 2001US-00816920.
PR   22-MAR-2001; 2001WO-US009552.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   30-JUL-2001; 2001US-00918585.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME;
PI   Goddard A,  Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ;
PI   Kljavin IJ,  Kuo SS,  Napier MA,  Pan J,  Paoni NF,  Roy MA,  Shelton DL;
PI   Stewart TA,  Tumas D,  Williams PM,  Wood WI;
XX
DR   WPI; 2003-341189/32.
DR   P-PSDB; ABU80388.
XX
PT   New genes and secreted and transmembrane polypeptides (e.g. PRO337 or
PT   PRO1559), useful for treating or diagnosing e.g. cancers,
PT   atherosclerosis, infertility, stroke, encephalitis, hepatitis or multiple
PT   sclerosis in mammals.
XX
PS   Claim 2; Fig 131; 460pp; English.
```

XX
CC The invention relates to a new isolated nucleic acid molecule comprises a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 94 PRO polypeptides whose sequences are fully defined in the
CC specification; or (b) any of 94 nucleotide sequences fully defined in the
CC specification; or the full length coding sequence of any these 94
CC nucleotide sequences. Also included are an isolated PRO polypeptide
CC scoring at least 80% positives when compared to any of the PRO
CC polypeptide sequences cited above (or an isolated PRO polypeptide having
CC at least 80% amino acid sequence identity to: (a) an amino acid sequence
CC encoded by the nucleotide deposited with ATCC numbers listed in the
CC specification; (b) the PRO polypeptide, lacking its associated signal
CC peptide; or (c) an extracellular domain of the PRO polypeptide, with or
CC lacking its associated signal peptide), a vector comprising the nucleic
CC acid molecule, a host cell comprising the vector (and producing a PRO
CC polypeptide), a chimaeric molecule comprising the PRO polypeptide fused
CC to a heterologous amino acid sequence and an anti-PRO antibody. The PRO
CC polypeptides or polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. These are particularly useful for
CC detecting or treating e.g. malignancies or cancers (e.g. ovarian cancer,
CC colorectal cancer, sarcoma, leukaemia or lymphoma), inflammatory disease,
CC necrosis, atherosclerosis, infertility, premature aging, psoriasis,
CC inflammatory disease, renal disease, arthritis, immune-mediated alopecia,
CC stroke, encephalitis, hepatitis, or multiple sclerosis in mammals. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence encodes a PRO polypeptide
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 18
ACA04159
ID ACA04159 standard; cDNA; 1174 BP.
XX
AC ACA04159;
XX
DT 27-MAY-2003 (first entry)
XX
DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 271.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioreactor; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-00137865.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-331925/31.
DR P-PSDB; ABU66981.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid further
CC comprises the full-length coding sequence of the DNA deposited under
CC American Type Culture Collection (ATCC) accession number in a list given
CC in the specification. Also included are vectors and host cells for
CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
CC extracellular domains and mature sequences, methods of detecting PRO
CC proteins, methods for stimulating the release of TNF-alpha (tumour
CC necrosis factor alpha) from human blood, (and the proliferation of
CC differentiation of chondrocyte cells, the proliferation of, or gene
CC expression in pericyte cells, the release or proteoglycans from
CC cartilage, proliferation of inner ear urticular supporting cells, the
CC proliferation of T-lymphocyte cells, the release of a cytokine from
CC peripheral blood mononuclear cells (PBMC), or the proliferation of
CC endothelial cells), a method for modulating the uptake of glucose or free
CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte
CC cells, a method for detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences cited
CC above. The nucleic acids and polypeptides are useful for treating
CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
CC infertility, birth defects, premature aging, AIDS (acquired
CC immunodeficiency syndrome), cancer, or diabetic complications. The
CC nucleic acids are useful as hybridisation probes, in chromosome and gene
CC mapping, and in generating antisense RNA or DNA. The polypeptides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both
CC are useful in tissue typing. The present sequence encodes a PRO protein
CC of the invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match             100.0%;  Score 1174;  DB 7;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 19
ADA45790
ID   ADA45790 standard; cDNA; 1174 BP.
XX
AC   ADA45790;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003022328-A1.
XX
PD   30-JAN-2003.
XX
PF   16-APR-2002; 2002US-00123904.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
```

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-584997/55.
DR P-PSDB; ADA45791.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
```

```
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 20
ADA76221
ID   ADA76221 standard; cDNA; 1174 BP.
XX
AC   ADA76221;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073212-A1.
XX
PD   17-APR-2003.
XX
PF   16-APR-2002; 2002US-00123903.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
```

PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-687639/65.
DR P-PSDB; ADA76222.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
```

```
Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 21
ADA18871
ID ADA18871 standard; cDNA; 1174 BP.
XX
AC ADA18871;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
PN US2003054517-A1.
XX
PD 20-MAR-2003.
XX
PF 08-MAY-2002; 2002US-00141755.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521854/49.
DR P-PSDB; ADA18872.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumors.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC prostate, rectal, cervical and liver tumours). The polynucleotides are
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA and in
CC gene therapy. The polynucleotides may also be used in preparing PRO
CC polypeptides by recombinant techniques and in generating either
CC transgenic animals or knock-out animals which are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polypeptides or antibodies are used in preparing a medicament for
CC treating a condition responsive to the polypeptides or antibodies, such
CC as tumours, for modulating the uptake of glucose or FFA by adipocyte
CC cells, for stimulating the proliferation of or gene expression in
CC pericyte cells, for stimulating the release of proteoglycans from
CC cartilage, for stimulating the proliferation of inner ear utricular
CC supporting cells, for stimulating the release of cytokines from PBMC
CC cells, for inhibiting the binding of A-peptide to factor VIIA, for
CC inhibiting the differentiation of adipocyte cells and for stimulating the
CC proliferation of endothelial cells. This sequence represents a human PRO
CC polynucleotide of the invention. Note: The sequence data for this patent
CC is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 22
ADA61494
ID ADA61494 standard; cDNA; 1174 BP.
XX
AC ADA61494;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO195.
OS cDNA.
XX
PN US2003049816-A1.
XX
PD 13-MAR-2003.
XX
PF 15-APR-2002; 2002US-00123262.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695892/66.
DR P-PSDB; ADA61495.
XX
PT New PRO nucleic acid and encode polypeptides, are useful for
PT manufacturing a medicament for diagnosing or treating cancer.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

```
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC   a novel human secreted and transmembrane PRO polypeptide.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 23
ADB19279
ID   ADB19279 standard; cDNA; 1174 BP.
XX
AC   ADB19279;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokin.
XX
OS   Homo sapiens.
XX
PN   US2003068796-A1.
XX
PD   10-APR-2003.
XX
PF   15-APR-2002; 2002US-00123261.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
```

PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695927/66.
DR P-PSDB; ADB19280.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
```

```
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174

Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 24
ADB27820
ID   ADB27820 standard; cDNA; 1174 BP.
XX
AC   ADB27820;
XX
DT   20-NOV-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082704-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131819.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-765415/72.
DR   P-PSDB; ADB27821.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence encodes a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 25
ADA86299
ID ADA86299 standard; cDNA; 1174 BP.
XX
AC ADA86299;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082711-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147508.
XX
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99US-0143048P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786914/74.
DR P-PSDB; ADA86300.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match             100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 26
ADB15863
ID ADB15863 standard; cDNA; 1174 BP.
XX
AC ADB15863;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087350-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127821.
XX
PR 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786941/74.
DR P-PSDB; ADB15864.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

```
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 27

```
ADA47649
ID   ADA47649 standard; cDNA; 1174 BP.
XX
AC   ADA47649;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073215-A1.
XX
PD   17-APR-2003.
XX
PF   07-MAY-2002; 2002US-00140925.
XX
PR   31-MAR-1997;    97WO-US005230.
PR   12-JUN-1998;    98WO-US012456.
PR   14-JUL-1998;    98WO-US014552.
PR   28-AUG-1998;    98WO-US017888.
PR   10-SEP-1998;    98WO-US018824.
PR   14-SEP-1998;    98WO-US019093.
PR   14-SEP-1998;    98WO-US019094.
```

PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-644801/61.
DR P-PSDB; ADA47650.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

```
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 28
ADA67444
ID   ADA67444 standard; cDNA; 1174 BP.
XX
AC   ADA67444;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068795-A1.
XX
PD   10-APR-2003.
XX
PF   15-APR-2002; 2002US-00123236.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
```

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-695926/66.
DR P-PSDB; ADA67445.
XX
PT Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy 61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy 241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

```
Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
            |||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 29
ADB30451
ID ADB30451 standard; cDNA; 1174 BP.
XX
AC ADB30451;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068794-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123155.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-708391/67.
DR P-PSDB; ADB30452.
XX
PT New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
```

```
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 30
ADA85747
ID ADA85747 standard; cDNA; 1174 BP.
XX
AC ADA85747;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082693-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127843.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786907/74.
DR P-PSDB; ADA85748.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
```

```
Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 31
ADA96959
ID ADA96959 standard; cDNA; 1174 BP.
XX
AC ADA96959;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082705-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131829.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755112/71.
DR P-PSDB; ADA96960.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 32
ADA79263
ID   ADA79263 standard; cDNA; 1174 BP.
XX
AC   ADA79263;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082763-A1.
XX
PD   01-MAY-2003.
XX
PF   17-APR-2002; 2002US-00124818.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
```

PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755116/71.
DR P-PSDB; ADA79264.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in detection and treatment of cancer and in modulating the uptake of
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
```

```
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174

Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 33
ADA87402
ID   ADA87402 standard; cDNA; 1174 BP.
XX
AC   ADA87402;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087345-A1.
XX
PD   08-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123907.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
```

PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786937/74.
DR P-PSDB; ADA87403.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 34
ADB16604
ID ADB16604 standard; cDNA; 1174 BP.
XX
AC ADB16604;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087349-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125928.
XX
PR 19-JUN-1998; 98US-0089947P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786940/74.
DR P-PSDB; ADB16605.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
```

```
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 35
ADA91696
ID ADA91696 standard; cDNA; 1174 BP.
XX
AC ADA91696;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082694-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127845.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786908/74.
DR P-PSDB; ADA91697.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT or a composition for treating e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match             100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
```

```
Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
            |||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 36
ADB14759
ID ADB14759 standard; cDNA; 1174 BP.
XX
AC ADB14759;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127822.
XX
PR 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786942/74.
DR P-PSDB; ADB14760.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 8; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
```

```
Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 37
ADA24868
ID   ADA24868 standard; cDNA; 1174 BP.
XX
AC   ADA24868;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss; tissue typing;
KW   chromosome identification; vaccine; cancer; retinal disorder;
KW   sports-related joint disorder; osteoarthritis; rheumatoid arthritis;
KW   wound healing; obesity; diabetes; hearing loss;
KW   cardiac insufficiency disorder; kidney disorder; nervous system disorder;
KW   haemoglobin associated disorder.
XX
OS   Homo sapiens.
XX
PN   US2003050241-A1.
XX
PD   13-MAR-2003.
XX
PF   16-OCT-2001; 2001US-00978564.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080107P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
```

PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-521814/49.
DR P-PSDB; ADA24869.
XX
PT New isolated PRO polypeptides for example extracellular, secreted and
PT membrane bound proteins, useful for modulating the biological activities
PT of cells and for treating, for example diabetes, cancer, rheumatoid
PT arthritis, and hearing loss.
XX
PS Claim 2; Fig 131; 461pp; English.
XX
CC The invention describes an isolated secreted and transmembrane (PRO)
CC polypeptide (I). PRO337 polypeptide is useful for detecting PRO4993
CC polypeptide in a sample, and vice versa. PRO725, PRO700 and PRO739 are
CC useful for detecting PRO1559 polypeptide in a sample, and PRO1559 is
CC useful for detecting PRO725, PRO700 and PRO739 in a sample. PRO4993 is
CC useful for linking a bioactive molecule to a cell expressing a PRO337
CC polypeptide, and PRO337 is useful for linking a bioactive molecule to a
CC cell expressing a PRO4993 polypeptide. PRO1559 is useful for linking a
CC bioactive molecule to a cell expressing a PRO735, PRO700 and PRO739

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 38
ADB18720
ID ADB18720 standard; cDNA; 1174 BP.
XX
AC ADB18720;
XX
DT 20-NOV-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokin.
XX
OS Homo sapiens.
XX
PN US2003073211-A1.
XX
PD 17-APR-2003.
XX
PF 15-APR-2002; 2002US-00123292.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695954/66.
DR P-PSDB; ADB18721.
XX
PT New isolated nucleic acid and encoded PRO polypeptide, are useful in the
PT diagnosis and treatment of cancer.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
                    ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 39
ADA93935
ID ADA93935 standard; cDNA; 1174 BP.
XX
AC ADA93935;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077722-A1.
XX
PD 24-APR-2003.
XX
PF 03-MAY-2002; 2002US-00137872.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755077/71.
DR P-PSDB; ADA93936.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 40
ADB19831
ID ADB19831 standard; cDNA; 1174 BP.
XX
AC ADB19831;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082691-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127838.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755108/71.
DR P-PSDB; ADB19832.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 8; Length 1174;
  Best Local Similarity   100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             |||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 41
ADB13143
ID ADB13143 standard; cDNA; 1174 BP.
XX
AC ADB13143;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082710-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147484.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786913/74.
DR P-PSDB; ADB13144.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT preparing a composition for treating e.g., tumor, or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 8; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
```

```
Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 42
ACD98559
ID   ACD98559 standard; cDNA; 1174 BP.
XX
AC   ACD98559;
XX
DT   26-SEP-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene therapy;
KW   chromosome identification; tissue typing; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003044945-A1.
XX
PD   06-MAR-2003.
XX
PF   10-MAY-2002; 2002US-00142419.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
```

PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-492275/46.
DR P-PSDB; ABO43284.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence encodes a novel human secreted and transmembrane
CC PRO polypeptide
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
```

```
Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 43
ACD29885
ID ACD29885 standard; cDNA; 1174 BP.
XX
AC ACD29885;
XX
DT 08-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; cell death; neuropathy;
KW peripheral neuropathy; diabetic peripheral neuropathy;
KW AIDS-associated neuropathy; Charcot-Marie-Tooth disease;
KW Refusum's disease; Abetalipoproteinaemia; Tangier disease;
KW Krabbe's disease; Metachromatic leukodystrophy; Fabry's disease;
KW Dejerine-Sottas syndrome; chromosome mapping; gene mapping; gene therapy;
KW gene; ss.
XX
OS Homo sapiens.
XX
PN US2003050240-A1.
XX
PD 13-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00978403.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.

PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WL;
XX
DR WPI; 2003-503575/47.
DR P-PSDB; ABO19690.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 2; Fig 131; 459pp; English.
XX
CC The invention describes an isolated, secreted and transmembrane
CC polypeptide, termed PRO polypeptide (I). (I) is useful for detecting
CC PRO4993, PRO337, PRO1559, PRO725, PRO700 or PRO739 polypeptide, and for
CC linking a bioactive molecule to a cell expressing the above polypeptides.
CC The bioactive molecule is a toxin, radiolabel or an antibody and causes
CC cell death. (I) is useful as therapeutic agent, in medical and industrial
CC applications e.g. for treating neuropathy, especially peripheral
CC neuropathy, diabetic peripheral neuropathy, AIDS-associated neuropathy,
CC Charcot-Marie-Tooth disease, Refusum's disease, Abetalipoproteinaemia,

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
```

```
Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 44
ADA12529
ID ADA12529 standard; cDNA; 1174 BP.
XX
AC ADA12529;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane polypeptide PRO195.
XX
KW ss; gene; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS; cancer;
KW diabetic complication; tissue typing; human.
XX
OS Homo sapiens.
XX
PN US2003055216-A1.
XX
PD 20-MAR-2003.
XX
PF 17-OCT-2001; 2001US-00978824.
XX
PR 21-MAY-1996; 96US-0018049P.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.

PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 21-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 45
ADA74397
ID   ADA74397 standard; cDNA; 1174 BP.
XX
AC   ADA74397;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068798-A1.
XX
PD   10-APR-2003.
XX
PF   07-MAY-2002; 2002US-00140928.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-625490/59.
DR   P-PSDB; ADA74398.
XX
PT   Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT   encoding them, useful for treating bone disorders, arthritis, heart
```

PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 46
ADB24630
ID ADB24630 standard; cDNA; 1174 BP.
XX
AC ADB24630;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX
OS Homo sapiens.
XX
PN US2003077713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755068/71.
DR P-PSDB; ADB24631.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
                  ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 47
ADA82154
ID ADA82154 standard; cDNA; 1174 BP.
XX
AC ADA82154;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082701-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128686.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755110/71.
DR P-PSDB; ADA82155.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 48
ADA75117
ID   ADA75117 standard; cDNA; 1174 BP.
XX
AC   ADA75117;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073216-A1.
XX
PD   17-APR-2003.
XX
PF   30-MAY-2002; 2002US-00160498.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
```

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-765392/72.
DR P-PSDB; ADA75118.
XX
PT New secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha in human blood and detecting
PT the presence of tumor in a mammal.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
                    ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 49
ADA85195
ID ADA85195 standard; cDNA; 1174 BP.
XX
AC ADA85195;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082695-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127846.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786909/74.
DR P-PSDB; ADA85196.
XX
PT New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT composition for treating e.g. tumor by gene therapy, or for tissue
PT typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
                |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 50
ADA84643
ID ADA84643 standard; cDNA; 1174 BP.
XX
AC ADA84643;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082708-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146729.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786911/74.
DR P-PSDB; ADA84644.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 51
ADB29899
ID   ADB29899 standard; cDNA; 1174 BP.
XX
AC   ADB29899;
XX
DT   20-NOV-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073214-A1.
XX
PD   17-APR-2003.
XX
PF   17-APR-2002; 2002US-00124822.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
```

PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-720081/68.
DR P-PSDB; ADB29900.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
                 ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 52
ADA80427
ID   ADA80427 standard; cDNA; 1174 BP.
XX
AC   ADA80427;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082761-A1.
XX
PD   01-MAY-2003.
XX
PF   12-APR-2002; 2002US-00121061.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755115/71.
DR   P-PSDB; ADA80428.
XX
```

PT New PRO polypeptides useful for treating diabetes, hyper- or hypo-
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT various coagulation disorders and tumors.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 53
ADA75669
ID ADA75669 standard; cDNA; 1174 BP.
XX
AC ADA75669;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082703-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128691.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zharg Z;
XX
DR WPI; 2003-765414/72.
DR P-PSDB; ADA75670.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
```

```
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 54
ADA46894
ID   ADA46894 standard; cDNA; 1174 BP.
XX
AC   ADA46894;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073210-A1.
XX
PD   17-APR-2003.
XX
PF   11-APR-2002; 2002US-00121045.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000;   2000WO-US000219.
PR   06-JAN-2000;   2000WO-US000277.
PR   06-JAN-2000;   2000WO-US000376.
PR   11-FEB-2000;   2000WO-US003565.
PR   18-FEB-2000;   2000WO-US004341.
PR   18-FEB-2000;   2000WO-US004342.
PR   22-FEB-2000;   2000WO-US004414.
PR   24-FEB-2000;   2000WO-US004914.
PR   24-FEB-2000;   2000WO-US005004.
PR   01-MAR-2000;   2000WO-US005601.
PR   02-MAR-2000;   2000WO-US005746.
PR   02-MAR-2000;   2000WO-US005841.
PR   10-MAR-2000;   2000WO-US006319.
PR   15-MAR-2000;   2000WO-US006884.
PR   20-MAR-2000;   2000WO-US007377.
PR   21-MAR-2000;   2000WO-US007532.
PR   30-MAR-2000;   2000WO-US008439.
PR   17-MAY-2000;   2000WO-US013705.
PR   22-MAY-2000;   2000WO-US014042.
PR   30-MAY-2000;   2000WO-US014941.
PR   02-JUN-2000;   2000WO-US015264.
PR   28-JUL-2000;   2000WO-US020710.
PR   11-AUG-2000;   2000WO-US022031.
PR   23-AUG-2000;   2000WO-US023522.
PR   24-AUG-2000;   2000WO-US023328.
PR   08-NOV-2000;   2000WO-US030952.
PR   10-NOV-2000;   2000WO-US030873.
PR   01-DEC-2000;   2000WO-US032678.
PR   20-DEC-2000;   2000US-00747259.
PR   20-DEC-2000;   2000WO-US034956.
PR   28-FEB-2001;   2001US-00796498.
PR   28-FEB-2001;   2001WO-US006520.
PR   01-MAR-2001;   2001WO-US006666.
PR   09-MAR-2001;   2001US-00802706.
PR   14-MAR-2001;   2001US-00808689.
PR   22-MAR-2001;   2001US-00816744.
PR   05-APR-2001;   2001US-00828366.
PR   10-MAY-2001;   2001US-00854208.
PR   10-MAY-2001;   2001US-00854280.
PR   18-MAY-2001;   2001US-00860216.
PR   25-MAY-2001;   2001US-00866028.
PR   25-MAY-2001;   2001US-00866034.
PR   25-MAY-2001;   2001WO-US017092.
PR   01-JUN-2001;   2001US-00872035.
PR   01-JUN-2001;   2001WO-US017800.
PR   05-JUN-2001;   2001US-00874503.
PR   14-JUN-2001;   2001US-00882636.
PR   19-JUN-2001;   2001US-00886342.
PR   20-JUN-2001;   2001WO-US019692.
PR   21-JUN-2001;   2001US-00887879.
PR   22-JUN-2001;   2001WO-US020116.
PR   29-JUN-2001;   2001WO-US021066.
PR   09-JUL-2001;   2001WO-US021735.
PR   18-JUL-2001;   2001US-00908827.
PR   06-AUG-2001;   2001US-00924419.
PR   09-AUG-2001;   2001US-00927796.
PR   16-AUG-2001;   2001US-00931836.
PR   19-DEC-2001;   2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-644800/61.
DR   P-PSDB; ADA46895.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 2; Fig 271; 638pp; English.
```

XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 55
ADB25190
ID ADB25190 standard; cDNA; 1174 BP.
XX
AC ADB25190;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077715-A1.

XX
PD 24-APR-2003.
XX
PF 23-APR-2002; 2002US-00128693.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755070/71.
DR P-PSDB; ADB25191.
XX
PT New isolated, secreted and transmembrane PRO nucleic acids, useful for
PT the diagnosis, prevention and/or treatment of tumors, such as lung,
PT colon, breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
                    ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 56
ADA93366
ID   ADA93366 standard; cDNA; 1174 BP.
XX
AC   ADA93366;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077721-A1.
XX
PD   24-APR-2003.
XX
PF   24-APR-2002; 2002US-00131837.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755076/71.
DR   P-PSDB; ADA93367.
XX
PT   New PRO nucleic acid, useful for recombinantly producing a PRO
PT   polypeptide and for manufacturing a medicament for diagnosing or treating
PT   tumor.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 57
ADB26716
ID   ADB26716 standard; cDNA; 1174 BP.
XX
AC   ADB26716;
XX
DT   20-NOV-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003092147-A1.
XX
PD   15-MAY-2003.
XX
PF   11-APR-2002; 2002US-00121051.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
```

PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777249/73.
DR P-PSDB; ADB26717.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 58
ADB31003
ID   ADB31003 standard; cDNA; 1174 BP.
XX
AC   ADB31003;
XX
DT   20-NOV-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003096386-A1.
XX
PD   22-MAY-2003.
XX
PF   11-APR-2002; 2002US-00121042.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786990/74.
DR   P-PSDB; ADB31004.
XX
PT   Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT   hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT   attack, various coagulation disorders, tumors.
XX
PS   Claim 2; Fig 271; 638pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
```

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 59
ADA60931
ID ADA60931 standard; cDNA; 1174 BP.
XX
AC ADA60931;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO195.
OS cDNA.

XX
PN US2003049817-A1.
XX
PD 13-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR 10-MAR-2009; 2000WO-US006319.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695893/66.
DR P-PSDB; ADA60932.
XX
PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful
PT for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 658pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 60
ADB24078
ID ADB24078 standard; cDNA; 1174 BP.
XX
AC ADB24078;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077714-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127901.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755069/71.
DR P-PSDB; ADB24079.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 61
ADA96407
ID ADA96407 standard; cDNA; 1174 BP.
XX
AC ADA96407;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082690-A1.
XX
PD 01-MAY-2003.
XX

PF 22-APR-2002; 2002US-00127837.
XX
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755107/71.
DR P-PSDB; ADA96408.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 62

ADA80979
ID ADA80979 standard; cDNA; 1174 BP.
XX
AC ADA80979;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082702-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128690.
XX
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755111/71.
DR P-PSDB; ADA80980.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
```

```
Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 63
ADA95855
ID ADA95855 standard; cDNA; 1174 BP.
XX
AC ADA95855;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082759-A1.
XX
PD 01-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121040.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755114/71.
DR P-PSDB; ADA95856.
XX
PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 64
ADB26164
ID ADB26164 standard; cDNA; 1174 BP.
XX
AC ADB26164;

XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082760-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121056.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777204/73.
DR P-PSDB; ADB26165.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 65
ADB21649
ID ADB21649 standard; cDNA; 1174 BP.
XX
AC ADB21649;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082765-A1.
XX
PD 01-MAY-2003.
XX
PF 17-MAY-2002; 2002US-00147492.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786920/74.
DR P-PSDB; ADB21650.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db        1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy       61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db       61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy      121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db      121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy      181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db      181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy      241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db      241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy      301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db      301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy      361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db      361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy      421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db      421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy      481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db      481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy      541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db      541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy      601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db      601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy      661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db      661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy      721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db      721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy      781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db      781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy      841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db      841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy      901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db      901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy      961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db      961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy     1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db     1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy     1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db     1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy     1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db     1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 66
ACD29300
ID ACD29300 standard; cDNA; 1174 BP.
XX
AC ACD29300;
XX
DT 27-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane polypeptide cDNA #83.
XX
KW Human; secreted and transmembrane protein; PRO; viral infection;
KW tumour growth; retinal disorder; injury; sight loss;
KW retinitis pigmentosum; age-related macular degeneration;
KW sport-related joint problem; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; wound healing; obesity; diabetes; insulinaemia;
KW kidney disorder; mesangial cell function; Berger disease; nephropathy;
KW celiac disease; dermatitis; Crohn disease; neuropathy;
KW cardiac- insufficiency disorder; peripheral neuropathy;
KW diabetic peripheral neuropathy; autonomic neuropathy;
KW reduced motility of the gastrointestinal tract;
KW atony of the urinary bladder; post polio syndrome; Krabbe's disease;
KW Charcot-Marie-Tooth disease; Fabry's disease; Tangier disease;
KW Refsum's disease; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049633-A1.
XX
PD 13-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00978585.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

```
Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             ||||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 67
ADA77428
ID ADA77428 standard; cDNA; 1174 BP.
XX
AC ADA77428;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068797-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140921.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625489/59.
DR P-PSDB; ADA77429.
XX
PT Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
PT and PRO1114, useful in the preparation of a medicament for treating a
PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.
PT vaccines.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 68
ADB18168
ID ADB18168 standard; cDNA; 1174 BP.
XX
AC ADB18168;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077710-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127825.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755065/71.
DR P-PSDB; ADB18169.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 8; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
```

```
Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 69
ADA86851
ID ADA86851 standard; cDNA; 1174 BP.
XX
AC ADA86851;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082709-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146791.
XX
PR 17-AUG-1998; 98US-0096895P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786912/74.
DR P-PSDB; ADA86852.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT for preparing a composition for treating e.g., tumor, or for tissue
PT typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the

```
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC   a novel human secreted and transmembrane PRO polypeptide.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 70
ADA87954
ID   ADA87954 standard; cDNA; 1174 BP.
XX
AC   ADA87954;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082700-A1.
XX
PD   01-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128684.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786910/74.
DR   P-PSDB; ADA87955.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
```

```
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC   a novel human secreted and transmembrane PRO polypeptide.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity 100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 71
ADA46342
ID   ADA46342 standard; cDNA; 1174 BP.
XX
AC   ADA46342;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003054516-A1.
XX
PD   20-MAR-2003.
XX
PF   12-APR-2002; 2002US-00121050.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
```

PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521853/49.
DR P-PSDB; ADA46343.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor.
XX
PS Claim 2; Fig 271; 200pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

```
Qy       61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy      121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy      181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy      241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy      301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy      361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy      421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy      481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy      541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy      601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy      661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy      721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy      781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy      841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy      901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy      961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy     1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy     1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy     1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
           ||||||||||||||||||||||||||||||||||
Db     1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 72
ADB28372
ID ADB28372 standard; cDNA; 1174 BP.
XX
AC ADB28372;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082699-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127851.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777202/73.
DR P-PSDB; ADB28373.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

```
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence encodes a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 73
ADB28924
ID   ADB28924 standard; cDNA; 1174 BP.
XX
AC   ADB28924;
XX
DT   20-NOV-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082706-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131836.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforgre L,  Desnoyers L,  Filvaroff E;
PI   Gao W,  Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-777203/73.
DR   P-PSDB; ADB28925.
XX
```

PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 74
ADA76876
ID ADA76876 standard; cDNA; 1174 BP.
XX
AC ADA76876;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX
OS Homo sapiens.
XX
PN US2003059909-A1.
XX
PD 27-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00143032.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-540684/51.
DR P-PSDB; ADA76877.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

```
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 75
ADA88506
ID   ADA88506 standard; cDNA; 1174 BP.
XX
AC   ADA88506;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003073213-A1.
XX
PD   17-APR-2003.
XX
PF   17-APR-2002; 2002US-00124819.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
```

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743816/70.
DR P-PSDB; ADA88507.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 76
ADA97511
ID   ADA97511 standard; cDNA; 1174 BP.
XX
AC   ADA97511;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082686-A1.
XX
PD   01-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125926.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755106/71.
DR   P-PSDB; ADA97512.
XX
PT   Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 2; Fig 271; 666pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
```

```
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 77
ADB27268
ID   ADB27268 standard; cDNA; 1174 BP.
XX
AC   ADB27268;
XX
DT   20-NOV-2003  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003022239-A1.
XX
PD   30-JAN-2003.
XX
PF   12-APR-2002; 2002US-00121049.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
PR   17-SEP-1997;   97US-0059184P.
PR   18-SEP-1997;   97US-0059263P.
PR   19-SEP-1997;   97US-0059352P.
PR   19-SEP-1997;   97US-0059588P.
PR   24-SEP-1997;   97US-0059836P.
PR   17-OCT-1997;   97US-0062250P.
PR   17-OCT-1997;   97US-0062285P.
PR   17-OCT-1997;   97US-0062287P.
PR   17-OCT-1997;   97US-0063755P.
PR   24-OCT-1997;   97US-0062814P.
PR   24-OCT-1997;   97US-0062816P.
PR   24-OCT-1997;   97US-0063045P.
PR   24-OCT-1997;   97US-0063082P.
PR   24-OCT-1997;   97US-0063127P.
PR   27-OCT-1997;   97US-0063327P.
PR   27-OCT-1997;   97US-0063329P.
PR   28-OCT-1997;   97US-0063550P.
PR   28-OCT-1997;   97US-0063561P.
PR   29-OCT-1997;   97US-0063704P.
PR   29-OCT-1997;   97US-0063733P.
PR   29-OCT-1997;   97US-0063735P.
```

PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.

```
  Query Match             100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 78
ADB22201
ID   ADB22201 standard; cDNA; 1174 BP.
XX
AC   ADB22201;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087344-A1.
XX
PD   08-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123905.
XX
PR   18-JUN-1997;    97US-0049911P.
PR   26-AUG-1997;    97US-0056974P.
PR   17-SEP-1997;    97US-0059113P.
PR   17-SEP-1997;    97US-0059115P.
PR   17-SEP-1997;    97US-0059117P.
PR   17-SEP-1997;    97US-0059122P.
PR   17-SEP-1997;    97US-0059184P.
PR   18-SEP-1997;    97US-0059263P.
PR   19-SEP-1997;    97US-0059352P.
PR   19-SEP-1997;    97US-0059588P.
PR   24-SEP-1997;    97US-0059836P.
PR   17-OCT-1997;    97US-0062250P.
PR   17-OCT-1997;    97US-0062285P.
PR   17-OCT-1997;    97US-0062287P.
PR   17-OCT-1997;    97US-0063755P.
PR   24-OCT-1997;    97US-0062814P.
PR   24-OCT-1997;    97US-0062816P.
PR   24-OCT-1997;    97US-0063045P.
PR   24-OCT-1997;    97US-0063082P.
PR   24-OCT-1997;    97US-0063127P.
PR   27-OCT-1997;    97US-0063327P.
PR   27-OCT-1997;    97US-0063329P.
PR   28-OCT-1997;    97US-0063550P.
PR   28-OCT-1997;    97US-0063561P.
PR   29-OCT-1997;    97US-0063704P.
PR   29-OCT-1997;    97US-0063733P.
PR   29-OCT-1997;    97US-0063735P.
PR   29-OCT-1997;    97US-0063738P.
PR   03-NOV-1997;    97US-0064248P.
PR   07-NOV-1997;    97US-0064809P.
PR   12-NOV-1997;    97US-0065186P.
PR   17-NOV-1997;    97US-0065846P.
PR   21-NOV-1997;    97US-0066364P.
```

PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.
PR 20-JAN-1999; 99US-0116533P.
PR 01-FEB-1999; 99US-0118210P.

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 79
ADA66892
ID ADA66892 standard; cDNA; 1174 BP.
XX
AC ADA66892;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068793-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123108.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.

```
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-695925/66.
DR   P-PSDB; ADA66893.
XX
PT   Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT   release of tumor necrosis factor-alpha from human blood and detecting the
PT   presence of a tumor in a mammal.
XX
PS   Claim 2; Fig 271; 660pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 80
ADB22753
ID   ADB22753 standard; cDNA; 1174 BP.
XX
AC   ADB22753;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077711-A1.
XX
PD   24-APR-2003.
XX
PF   22-APR-2002; 2002US-00127829.
XX
PR   22-OCT-1998;   98US-0105169P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   30-NOV-1999;   99WO-US028313.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755066/71.
DR   P-PSDB; ADB22754.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT   in gene therapy, as diagnostic markers for the presence of a disease
PT   condition, or as therapeutic targets for treating tumors, diabetes,
PT   obesity or arthritis.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 8;  Length 1174;
  Best Local Similarity 100.0%;  Pred. No. 0;
```

```
 Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 81
ADB23526
ID ADB23526 standard; cDNA; 1174 BP.
XX
AC ADB23526;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077712-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127835.
XX
PR 20-OCT-1998; 98US-0104987P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755067/71.
DR P-PSDB; ADB23527.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 82
ADA92248
ID ADA92248 standard; cDNA; 1174 BP.
XX
AC ADA92248;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082712-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147512.
XX
PR 15-MAY-1998; 98US-0085697P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786915/74.
DR P-PSDB; ADA92249.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 83
ADB15311
ID ADB15311 standard; cDNA; 1174 BP.
XX
AC ADB15311;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX
OS Homo sapiens.
XX
PN US2003087352-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127824.
XX
PR 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786943/74.
DR P-PSDB; ADB15312.
XX
PT New PRO nucleic acid, useful for producing a recombiannt PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             ||||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 84
ADB38563
ID ADB38563 standard; cDNA; 1174 BP.
XX
AC ADB38563;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082766-A1.
XX
PD 01-MAY-2003.
XX
PF 30-MAY-2002; 2002US-00158782.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786921/74.
DR P-PSDB; ADB38564.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.

XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 85
ADB38011
ID ADB38011 standard; cDNA; 1174 BP.
XX
AC ADB38011;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087347-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125921.
XX

PR 17-AUG-1998; 98US-0096791P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786938/74.
DR P-PSDB; ADB38012.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 86
ADB66483
ID ADB66483 standard; cDNA; 1174 BP.
XX
AC ADB66483;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082689-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127831.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786905/74.
DR P-PSDB; ADB66484.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 87
ADB89563
ID ADB89563 standard; cDNA; 1174 BP.
XX
AC ADB89563;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082698-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127850.
XX
PR 20-AUG-1998; 98US-0097218P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743896/70.

DR P-PSDB; ADB89564.
XX
PT New PRO nucleic acids and encoded polypeptides, useful in the treatment
PT of cancer.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy 1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
          |||||||||||||||||||||||||||||||||
Db 1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 88
ADB90295
ID ADB90295 standard; cDNA; 1174 BP.
XX
AC ADB90295;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082762-A1.
XX
PD 01-MAY-2003.
XX
PF 15-APR-2002; 2002US-00123235.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743899/70.
DR P-PSDB; ADB90296.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, and in the detection and treatment of tumor in a mammal.
XX
PS Claim 2; Fig 271; 649pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

```
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 89
ADB39396
ID   ADB39396 standard; cDNA; 1174 BP.
XX
AC   ADB39396;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082764-A1.
XX
PD   01-MAY-2003.
XX
PF   03-MAY-2002; 2002US-00137868.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
```

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786919/74.
DR P-PSDB; ADB39397.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 90
ADB73835
ID   ADB73835 standard; cDNA; 1174 BP.
XX
AC   ADB73835;
XX
DT   04-DEC-2003 (first entry)

XX
DE   Human PRO polynucleotide sequence #83.
XX
KW   Human; PRO polypeptide; secreted protein; transmembrane protein;
KW   cell death; neuropathy; neuropathy related disease;
KW   Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW   chromosome mapping; gene mapping; genetic disorder; septic shock;
KW   antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003045462-A1.
XX
PD   06-MAR-2003.
XX
PF   16-OCT-2001; 2001US-00978608.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080107P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.

PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
```

```
Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 91
ADB47019
ID ADB47019 standard; cDNA; 1174 BP.
XX
AC ADB47019;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082687-A1.
XX
PD 01-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125930.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786904/74.
DR P-PSDB; ADB47020.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 627pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
```

```
Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             |||||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 92
ADB86626
ID ADB86626 standard; cDNA; 1174 BP.
XX
AC ADB86626;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082697-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127849.
XX
PR 20-OCT-1998; 98US-0104987P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743895/70.
DR P-PSDB; ADB86627.
XX
PT New secreted and transmembrane PRO polypeptides, useful in the diagnosis
PT and treatment of cancer.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 93
ADB76551
ID ADB76551 standard; cDNA; 1174 BP.
XX
AC ADB76551;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide sequence #83.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003083248-A1.
XX
PD 01-MAY-2003.
XX
PF 16-OCT-2001; 2001US-00978757.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-755118/71.
DR P-PSDB; ADB76552.
XX
PT New PRO polypeptides useful for treating peripheral neuropathy,
PT neuropathies associated with systemic disease such as post-polio syndrome
PT or AIDS-associated syndrome.
XX
PS Claim 2; Fig 131; 425pp; English.

```
XX
CC   The present invention relates to the isolation of novel human PRO
CC   polypeptides, and the polynucleotide sequences encoding them. The PRO
CC   polypeptides are secreted and transmembrane proteins. The PRO
CC   polypeptides are useful for detecting other PRO polypeptides, for linking
CC   bioactive molecules to cells expressing PRO polypeptides, for modulating
CC   biological activities of cells expressing PRO polypeptides, and for
CC   identifying agonists or antagonists. The bioactive molecule maybe a
CC   toxin, radiolabel or antibody, and cause cell death. The PRO polypeptides
CC   are useful for treating neuropathy and neuropathy related diseases such
CC   as Charcot-Marie-Tooth disorder, Refsum's disease, and Krabbe's disease.
CC   The polynucleotide sequences encoding PRO polypeptides are useful as
CC   hybridisation probes, in chromosome and gene mapping, in the generation

  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 94
ADB77231
ID   ADB77231 standard; cDNA; 1174 BP.
XX
AC   ADB77231;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082696-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127848.
XX
PR   03-NOV-1998;   98US-0106934P.
PR   26-JUL-1999;   99US-0145698P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   05-JAN-2000; 2000WO-US000219.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755109/71.
DR   P-PSDB; ADB77232.
XX
PT   PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT   tumor or for tissue typing.
```

XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 95
ADB34388
ID ADB34388 standard; cDNA; 1174 BP.
XX
AC ADB34388;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077717-A1.
XX
PD 24-APR-2003.
XX

PF 24-APR-2002; 2002US-00131818.
XX
PR 07-OCT-1998; 98US-0103328P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755072/71.
DR P-PSDB; ADB34389.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 96
ADB35492
ID ADB35492 standard; cDNA; 1174 BP.
XX
AC ADB35492;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077719-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131824.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755074/71.
DR P-PSDB; ADB35493.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
```

```
Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 97
ADB33836
ID ADB33836 standard; cDNA; 1174 BP.
XX
AC ADB33836;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077716-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131813.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755071/71.
DR P-PSDB; ADB33837.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
```

```
Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
            ||||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 98
ADB34940
ID ADB34940 standard; cDNA; 1174 BP.
XX
AC ADB34940;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077718-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131823.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755073/71.
DR P-PSDB; ADB34941.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 99
ADB36044
ID ADB36044 standard; cDNA; 1174 BP.
XX
AC ADB36044;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077720-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131830.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755075/71.
DR P-PSDB; ADB36045.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 9; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 100
ADB46439
ID ADB46439 standard; cDNA; 1174 BP.
XX
AC ADB46439;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082692-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127842.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786906/74.
DR P-PSDB; ADB46440.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 101
ADC43977
ID   ADC43977 standard; cDNA; 1174 BP.
XX
AC   ADC43977;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003054986-A1.
XX
PD   20-MAR-2003.
XX
PF   16-OCT-2001; 2001US-00981915.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080107P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.
```

PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
```

```
Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 102
ADC61737
ID ADC61737 standard; cDNA; 1174 BP.
XX
AC ADC61737;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnerary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003049684-A1.
XX
PD 13-MAR-2003.
XX
PF 24-OCT-2001; 2001US-00017081.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.

PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
```

```
Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 103
ADC63701
ID ADC63701 standard; cDNA; 1174 BP.
XX
AC ADC63701;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnerary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003054405-A1.
XX
PD 20-MAR-2003.
XX
PF 24-OCT-2001; 2001US-00999833.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.

PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
```

```
Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 104
ADC66801
ID   ADC66801 standard; cDNA; 1174 BP.
XX
AC   ADC66801;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   vulnerary; virucide; neuroprotective; cytostatic; gene therapy;
KW   tumour cell proliferation inihibitor;
KW   secereted and transmembrane protein; PRO; viral infection; wound healing;
KW   tissue growth; muscle generation; muscle regeneration;
KW   amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW   diabetic peripheral neuropathy; chromosome identification; antagonist;
KW   tissue typing; immunohistochemical staining; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003060406-A1.
XX
PD   27-MAR-2003.
XX
PF   30-JUL-2001; 2001US-00918585.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   26-JUN-1998;   98US-00105413.
PR   07-OCT-1998;   98US-00168978.
PR   07-OCT-1998;   98WO-US021141.
PR   02-NOV-1998;   98US-00184216.
PR   06-NOV-1998;   98US-00187368.
PR   20-NOV-1998;   98WO-US024855.
PR   07-DEC-1998;   98US-00202054.
PR   22-DEC-1998;   98US-00218517.
PR   05-JAN-1999;   99WO-US000106.
PR   05-MAR-1999;   99US-00254465.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99US-00265686.
PR   10-MAR-1999;   99WO-US005190.
PR   12-MAR-1999;   99US-00267213.
PR   12-APR-1999;   99US-00284291.
PR   14-MAY-1999;   99US-00311832.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   25-AUG-1999;   99US-00380138.
PR   25-AUG-1999;   99US-00380142.
PR   30-NOV-1999;   99WO-US028313.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
```

PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-596568/56.
DR P-PSDB; ADC66802.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them, useful for treating wound healing, tissue growth and
PT muscle generation and regeneration, amyotrophic lateral sclerosis or
PT neuropathy.
XX
PS Claim 2; SEQ ID NO 329; 472pp; English.
XX
CC The invention describes an isolated secereted and transmembrane PRO
CC polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
CC is useful in biotechnological and medical research, as well as in various
CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
CC PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853,
CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
CC therapeutically in vivo for lessening the effects of viral infection.
CC PRO200 is useful for the treatment of wound healing, tissue growth and
CC muscle generation and regeneration. PRO337 is useful for treating
CC amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
CC diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
CC useful for generating transgenic animals or knockout animals which are
CC useful in the development and screening of therapeutically useful
CC reagents, as probes for generating a pool of sequences for identifying
CC related PRO coding sequences, and to construct hybridisation probes for
CC mapping the gene which encodes the PRO and for the genetic analysis of
CC individuals with genetic disorders, for recombinantly expressing (I) and
CC for chromosome identification. (I) is useful as molecular marker for
CC protein electrophoresis purposes, and as therapeutic agents. (I) is also
CC useful for screening compounds to identify those that mimic the PRO
CC polypeptide (agonists) or prevent the effect of the PRO polypeptide
CC (antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
CC are useful for immunohistochemical staining and/or assay of sample
CC fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence encodes a human secereted and transmembrane PRO
CC protein.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
```

```
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 105
ADC68925
ID   ADC68925 standard; cDNA; 1174 BP.
XX
AC   ADC68925;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003064407-A1.
XX
PD   03-APR-2003.
XX
PF   24-OCT-2001; 2001US-00999834.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080107P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.
PR   29-APR-1998;   98US-0083500P.
PR   29-APR-1998;   98US-0083545P.
PR   29-APR-1998;   98US-0083554P.
PR   29-APR-1998;   98US-0083558P.
PR   29-APR-1998;   98US-0083559P.
PR   30-APR-1998;   98US-0083742P.
PR   05-MAY-1998;   98US-0084366P.
PR   06-MAY-1998;   98US-0084414P.
PR   06-MAY-1998;   98US-0084441P.
PR   07-MAY-1998;   98US-0084598P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   07-MAY-1998;   98US-0084639P.
PR   07-MAY-1998;   98US-0084640P.
PR   07-MAY-1998;   98US-0084643P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085573P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085580P.
PR   15-MAY-1998;   98US-0085582P.
PR   15-MAY-1998;   98US-0085689P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085700P.
PR   15-MAY-1998;   98US-0085704P.
PR   18-MAY-1998;   98US-0086023P.
PR   22-MAY-1998;   98US-0086392P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   22-MAY-1998;   98US-0086486P.
PR   28-MAY-1998;   98US-0087098P.
PR   28-MAY-1998;   98US-0087106P.
PR   28-MAY-1998;   98US-0087208P.
PR   26-JUN-1998;   98US-00105413.
PR   26-JUN-1998;   98US-0090863P.
PR   26-JUN-1998;   98US-0091010P.
PR   01-JUL-1998;   98US-0091359P.
PR   30-JUL-1998;   98US-0094651P.
PR   11-SEP-1998;   98US-0100038P.
PR   07-OCT-1998;   98US-00168978.
PR   07-OCT-1998;   98WO-US021141.
PR   02-NOV-1998;   98US-00184216.
PR   06-NOV-1998;   98US-00187368.
PR   20-NOV-1998;   98US-0109304P.
PR   20-NOV-1998;   98WO-US024855.
PR   07-DEC-1998;   98US-00202054.
PR   22-DEC-1998;   98US-00218517.
PR   22-DEC-1998;   98US-0113296P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   05-MAR-1999;   99US-00254465.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99US-00265686.
```

PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 106
ADC62985
ID   ADC62985 standard; cDNA; 1174 BP.
XX
AC   ADC62985;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003068648-A1.
XX
PD   10-APR-2003.
XX
PF   25-OCT-2001; 2001US-00013921.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080107P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.
PR   29-APR-1998;   98US-0083500P.
PR   29-APR-1998;   98US-0083545P.
PR   29-APR-1998;   98US-0083554P.
PR   29-APR-1998;   98US-0083558P.
PR   29-APR-1998;   98US-0083559P.
PR   30-APR-1998;   98US-0083742P.
PR   05-MAY-1998;   98US-0084366P.
PR   06-MAY-1998;   98US-0084414P.
PR   06-MAY-1998;   98US-0084441P.
PR   07-MAY-1998;   98US-0084598P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   07-MAY-1998;   98US-0084639P.
PR   07-MAY-1998;   98US-0084640P.
PR   07-MAY-1998;   98US-0084643P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085573P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085580P.
PR   15-MAY-1998;   98US-0085582P.
PR   15-MAY-1998;   98US-0085689P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085700P.
PR   15-MAY-1998;   98US-0085704P.
PR   18-MAY-1998;   98US-0086023P.
PR   22-MAY-1998;   98US-0086392P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   22-MAY-1998;   98US-0086486P.
PR   28-MAY-1998;   98US-0087098P.
PR   28-MAY-1998;   98US-0087106P.
PR   28-MAY-1998;   98US-0087208P.
PR   26-JUN-1998;   98US-0090863P.
PR   26-JUN-1998;   98US-0091010P.
PR   01-JUL-1998;   98US-0091359P.
PR   30-JUL-1998;   98US-0094651P.
PR   11-SEP-1998;   98US-0100038P.
PR   07-OCT-1998;   98WO-US021141.
PR   20-NOV-1998;   98US-0109304P.
PR   20-NOV-1998;   98WO-US024855.
PR   22-DEC-1998;   98US-0113296P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   12-MAR-1999;   99US-0123957P.
PR   29-MAR-1999;   99US-0126773P.
PR   21-APR-1999;   99US-0130232P.
PR   26-APR-1999;   99US-0131022P.
PR   28-APR-1999;   99US-0131445P.
PR   14-MAY-1999;   99US-0134287P.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   16-JUN-1999;   99US-0139557P.
PR   30-NOV-1999;   99WO-US028313.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
```

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-695924/66.
DR P-PSDB; ADC62986.
XX
PT New isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 329; 467pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
```

```
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 107
ADC68050
ID   ADC68050 standard; cDNA; 1174 BP.
XX
AC   ADC68050;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003069178-A1.
XX
PD   10-APR-2003.
XX
PF   16-OCT-2001; 2001US-00978423.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.
PR   29-APR-1998;   98US-0083500P.
PR   29-APR-1998;   98US-0083545P.
PR   29-APR-1998;   98US-0083554P.
PR   29-APR-1998;   98US-0083558P.
PR   29-APR-1998;   98US-0083559P.
PR   30-APR-1998;   98US-0083742P.
PR   05-MAY-1998;   98US-0084366P.
PR   06-MAY-1998;   98US-0084414P.
PR   06-MAY-1998;   98US-0084441P.
PR   07-MAY-1998;   98US-0084598P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   07-MAY-1998;   98US-0084639P.
PR   07-MAY-1998;   98US-0084640P.
PR   07-MAY-1998;   98US-0084643P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085573P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085580P.
PR   15-MAY-1998;   98US-0085582P.
PR   15-MAY-1998;   98US-0085689P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085700P.
PR   15-MAY-1998;   98US-0085704P.
PR   18-MAY-1998;   98US-0086023P.
PR   22-MAY-1998;   98US-0086392P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   22-MAY-1998;   98US-0086486P.
PR   28-MAY-1998;   98US-0087098P.
PR   28-MAY-1998;   98US-0087106P.
PR   28-MAY-1998;   98US-0087208P.
PR   26-JUN-1998;   98US-0090863P.
PR   26-JUN-1998;   98US-0091010P.
PR   01-JUL-1998;   98US-0091359P.
PR   30-JUL-1998;   98US-0094651P.
PR   11-SEP-1998;   98US-0100038P.
PR   07-OCT-1998;   98WO-US021141.
PR   20-NOV-1998;   98US-0109304P.
PR   20-NOV-1998;   98WO-US024855.
PR   22-DEC-1998;   98US-0113296P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   12-MAR-1999;   99US-0123957P.
PR   29-MAR-1999;   99US-0126773P.
PR   21-APR-1999;   99US-0130232P.
PR   26-APR-1999;   99US-0131022P.
PR   28-APR-1999;   99US-0131445P.
PR   14-MAY-1999;   99US-0134287P.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   16-JUN-1999;   99US-0139557P.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0142680P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   29-OCT-1999;   99US-0162506P.
PR   30-NOV-1999;   99WO-US028313.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
```

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-657582/62.
DR P-PSDB; ADC68051.
XX
PT Novel secreted and transmembrane polypeptides, designated PRO
PT polypeptides, and polynucleotides encoding them useful for treating
PT kidney diseases, bone, cartilage and retinal disorders.
XX
PS Claim 2; SEQ ID NO 329; 468pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 108

```
ADC41370
ID   ADC41370 standard; cDNA; 1174 BP.
XX
AC   ADC41370;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003072745-A1.
XX
PD   17-APR-2003.
XX
PF   25-OCT-2001; 2001US-00013929.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080107P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.
PR   29-APR-1998;   98US-0083500P.
PR   29-APR-1998;   98US-0083545P.
PR   29-APR-1998;   98US-0083554P.
PR   29-APR-1998;   98US-0083558P.
PR   29-APR-1998;   98US-0083559P.
PR   30-APR-1998;   98US-0083742P.
PR   05-MAY-1998;   98US-0084366P.
PR   06-MAY-1998;   98US-0084414P.
PR   06-MAY-1998;   98US-0084441P.
PR   07-MAY-1998;   98US-0084598P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   07-MAY-1998;   98US-0084639P.
PR   07-MAY-1998;   98US-0084640P.
PR   07-MAY-1998;   98US-0084643P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085573P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085580P.
PR   15-MAY-1998;   98US-0085582P.
PR   15-MAY-1998;   98US-0085689P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085700P.
PR   15-MAY-1998;   98US-0085704P.
PR   18-MAY-1998;   98US-0086023P.
PR   22-MAY-1998;   98US-0086392P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   22-MAY-1998;   98US-0086486P.
PR   28-MAY-1998;   98US-0087098P.
PR   28-MAY-1998;   98US-0087106P.
PR   28-MAY-1998;   98US-0087208P.
PR   26-JUN-1998;   98US-0090863P.
PR   26-JUN-1998;   98US-0091010P.
PR   01-JUL-1998;   98US-0091359P.
PR   30-JUL-1998;   98US-0094651P.
PR   11-SEP-1998;   98US-0100038P.
PR   07-OCT-1998;   98WO-US021141.
PR   20-NOV-1998;   98US-0109304P.
PR   20-NOV-1998;   98WO-US024855.
PR   22-DEC-1998;   98US-0113296P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   12-MAR-1999;   99US-0123957P.
PR   29-MAR-1999;   99US-0126773P.
PR   21-APR-1999;   99US-0130232P.
PR   26-APR-1999;   99US-0131022P.
PR   28-APR-1999;   99US-0131445P.
PR   14-MAY-1999;   99US-0134287P.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   16-JUN-1999;   99US-0139557P.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0142680P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   29-OCT-1999;   99US-0162506P.
PR   30-NOV-1999;   99WO-US028313.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
```

PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-743806/70.
DR P-PSDB; ADC41371.
XX
PT Novel isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 329; 466pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 109
ADC67425
ID ADC67425 standard; cDNA; 1174 BP.
XX
AC ADC67425;

XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW vulnerary; virucide; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inihibitor;
KW secereted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003073131-A1.
XX
PD 17-APR-2003.
XX
PF 25-OCT-2001; 2001US-00016177.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-743810/70.
DR P-PSDB; ADC67426.
XX
PT Novel isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 329; 464pp; English.
XX
CC The invention describes an isolated secereted and transmembrane PRO
CC polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
CC is useful in biotechnological and medical research, as well as in various
CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
CC PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853,
CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
CC therapeutically in vivo for lessening the effects of viral infection.
CC PRO200 is useful for the treatment of wound healing, tissue growth and
CC muscle generation and regeneration. PRO337 is useful for treating

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 110
ADC62361
ID ADC62361 standard; cDNA; 1174 BP.
XX
AC ADC62361;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.

XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnerary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003073624-A1.
XX
PD 17-APR-2003.
XX
PF 15-OCT-2001; 2001US-00978193.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.

PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 04-FEB-2000; 2000US-0180165P.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 111
ADC41994
ID ADC41994 standard; cDNA; 1174 BP.
XX
AC ADC41994;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnerary; auditory; tumour growth; retinal disorder;

KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003104998-A1.
XX
PD 05-JUN-2003.
XX
PF 16-OCT-2001; 2001US-00978643.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 112
ADC50312
ID ADC50312 standard; cDNA; 1174 BP.
XX
AC ADC50312;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003092106-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131822.
XX
PR 19-AUG-1998; 98US-0097141P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801171/75.
DR P-PSDB; ADC50313.
XX
PT New secreted and transmembrane nucleic acid useful for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome or cancer.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
```

```
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
                    ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 113
ADC71859
ID ADC71859 standard; cDNA; 1174 BP.
XX
AC ADC71859;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003092107-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131828.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801172/75.
DR P-PSDB; ADC71860.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
```

```
Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             ||||||||||||||||||||||||||||||||||
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 114
ADC59838
ID ADC59838 standard; cDNA; 1174 BP.
XX
AC ADC59838;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003092105-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131821.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801170/75.
DR P-PSDB; ADC59839.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy       181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
                |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 115
ADC52845
ID   ADC52845 standard; cDNA; 1174 BP.
XX
AC   ADC52845;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS   Homo sapiens.
XX
PN   US2003087365-A1.
XX
PD   08-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128689.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
```

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godwoski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801150/75.
DR P-PSDB; ADC52846.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
```

```
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 116
ADC57199
ID ADC57199 standard; cDNA; 1174 BP.
XX
AC ADC57199;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087366-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128694.
XX
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801151/75.
DR P-PSDB; ADC57200.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
```

```
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 117
ADC60390
ID ADC60390 standard; cDNA; 1174 BP.
XX
AC ADC60390;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087367-A1.
XX
PD 08-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131825.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801152/75.
DR P-PSDB; ADC60391.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
```

```
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174

RESULT 118
ADC50865
ID   ADC50865 standard; cDNA; 1174 BP.
XX
AC   ADC50865;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003087361-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127841.
XX
PR   09-SEP-1998;   98US-0099536P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801146/75.
DR   P-PSDB; ADC50866.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polynucleotide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
```

```
Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 119
ADC65392
ID ADC65392 standard; cDNA; 1174 BP.
XX
AC ADC65392;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS *Homo sapiens*.
XX
PN US2003087362-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127844.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801147/75.
DR P-PSDB; ADC65393.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 9; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
```

```
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 120
ADC54490
ID   ADC54490 standard; cDNA; 1174 BP.
XX
AC   ADC54490;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS   Homo sapiens.
XX
PN   US2003087363-A1.
XX
PD   08-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128687.
XX
PR   10-SEP-1998;   98US-0099816P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801148/75.
DR   P-PSDB; ADC54491.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is a cDNA sequence which encodes a human PRO protein of the
CC   invention.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
```

```
  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
```

```
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 121
ADC53451
ID   ADC53451 standard; cDNA; 1174 BP.
XX
AC   ADC53451;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS   Homo sapiens.
XX
PN   US2003087364-A1.
XX
PD   08-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128688.
XX
PR   09-FEB-1999;   99US-0119341P.
PR   01-DEC-1999;   99WO-US028634.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801149/75.
DR   P-PSDB; ADC53452.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is a cDNA sequence which encodes a human PRO protein of the
CC   invention.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Qy       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db       241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db       301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db       361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db       421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db       481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db       541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db       601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db       661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db       721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db       781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db       841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db       901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db       961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db      1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db      1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db      1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 122
ADC58974
ID ADC58974 standard; cDNA; 1174 BP.
XX
AC ADC58974;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087359-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127834.
XX
PR 17-SEP-1998; 98US-0100710P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801144/75.
DR P-PSDB; ADC58975.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db         1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db        61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
```

```
Qy      121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db      121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy      181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db      181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy      241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db      241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy      301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db      301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy      361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db      361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy      421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db      421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy      481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db      481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy      541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db      541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy      601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db      601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy      661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db      661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy      721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db      721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy      781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db      781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy      841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db      841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy      901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db      901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy      961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db      961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy     1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db     1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy     1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db     1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy     1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db     1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 123
ADC55852
ID ADC55852 standard; cDNA; 1174 BP.
XX
AC ADC55852;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087360-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127836.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801145/75.
DR P-PSDB; ADC55853.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

```
Best Local Similarity   100.0%;  Pred. No. 0;
Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 124
ADC58422
ID   ADC58422 standard; cDNA; 1174 BP.
XX
AC   ADC58422;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein cDNA Seq ID271.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS   Homo sapiens.
XX
PN   US2003087346-A1.
XX
PD   08-MAY-2003.
XX
PF   17-APR-2002; 2002US-00124815.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801137/75.
DR   P-PSDB; ADC58423.
XX
PT   Isolated nucleic acid for use in industrial applications has at least 80
PT   percent nucleic acid sequence identity to nucleotide sequence that
PT   encodes amino acid sequence selected from amino acid sequence group.
XX
PS   Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
```

```
CC   sequence is a cDNA sequence which encodes a human PRO protein of the
CC   invention.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 125
ADD03096
ID   ADD03096 standard; cDNA; 1174 BP.
XX
AC   ADD03096;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS   Homo sapiens.
XX
PN   US2003092104-A1.
XX
PD   15-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131817.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
```

PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801169/75.
DR P-PSDB; ADD03097.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
```

```
Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 126
ADC90088
ID ADC90088 standard; cDNA; 1174 BP.
XX
AC ADC90088;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087348-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125923.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786939/74.
DR P-PSDB; ADC90089.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
```

```
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
               ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 127
ADC69507
ID ADC69507 standard; cDNA; 1174 BP.
XX
AC ADC69507;
XX
DT 01-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194770-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152375.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844453/78.
DR P-PSDB; ADC69508.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

```
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence encodes a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 128
ADC48396
ID   ADC48396 standard; cDNA; 1174 BP.
XX
AC   ADC48396;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194773-A1.
XX
PD   16-OCT-2003.
XX
PF   21-MAY-2002; 2002US-00152391.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   30-MAY-2000; 2000WO-US014941.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-844455/78.
```

DR P-PSDB; ADC48397.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha and stimulating the proliferation of endothelial cells.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 129
ADD09925
ID ADD09925 standard; cDNA; 1174 BP.
XX
AC ADD09925;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194776-A1.
XX
PD 16-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157785.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852596/79.
DR P-PSDB; ADD09926.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
             |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 130
ADD04500
ID ADD04500 standard; cDNA; 1174 BP.
XX
AC ADD04500;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087354-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127827.
XX
PR 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801139/75.
DR P-PSDB; ADD04501.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
```

```
Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 131
ADC80456
ID ADC80456 standard; cDNA; 1174 BP.
XX
AC ADC80456;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003092103-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131815.
XX
PR 22-DEC-1998; 98US-0113511P.
PR 01-DEC-1999; 99WO-US028634.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801168/75.
DR P-PSDB; ADC80457.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```
  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
```

```
Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 132
ADD10963
ID ADD10963 standard; cDNA; 1174 BP.
XX
AC ADD10963;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194774-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152399.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852594/79.
DR P-PSDB; ADD10964.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the proliferation or differentiation
PT of chondrocyte cells and stimulating the release of tumor necrosis factor
PT alpha.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 133
ADD10296
ID ADD10296 standard; cDNA; 1174 BP.
XX
AC ADD10296;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane PRO polypeptide cDNA #4.
XX
KW ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX
OS Homo sapiens.
XX
PN US2003105011-A1.
XX
PD 05-JUN-2003.
XX
PF 16-AUG-2002; 2002US-00223084.
XX
PR 15-SEP-2000; 2000US-0232887P.
PR 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2003-810831/76.
DR P-PSDB; ADD10297.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.
XX
PS Claim 2; SEQ ID NO 7; 493pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGF-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.

```
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match            100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 134
ADC47844
ID   ADC47844 standard; cDNA; 1174 BP.
XX
AC   ADC47844;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194771-A1.
XX
PD   16-OCT-2003.
XX
PF   21-MAY-2002; 2002US-00152377.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Gurney SL,  Smith V;
PI   Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-844454/78.
DR   P-PSDB; ADC47845.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT   for detecting a tumor, stimulating the release of proteoglycans from
PT   cartilage and stimulating the proliferation of endothelial cells.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
```

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 135
ADC79904
ID ADC79904 standard; cDNA; 1174 BP.
XX
AC ADC79904;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087358-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127833.
XX
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.

PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801143/75.
DR P-PSDB; ADC79905.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy 1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
          |||||||||||||||||||||||||||||||||
Db 1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 136
ADD11256
ID ADD11256 standard; cDNA; 1174 BP.
XX
AC ADD11256;
XX
DT 01-JAN-2004 (first entry)

XX
DE Human secreted/transmembrane PRO polypeptide cDNA #4.
XX
KW ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX
OS Homo sapiens.
XX
PN US2003105013-A1.
XX
PD 05-JUN-2003.
XX
PF 16-AUG-2002; 2002US-00223090.
XX
PR 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2003-801242/75.
DR P-PSDB; ADD11257.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, useful for treating a cardiovascular, endothelial, or
PT angiogenic disorder in a mammal, such as cancer or age-related macular
PT degeneration.
XX
PS Claim 2; SEQ ID NO 7; 493pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGF-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 137
ADD09373
ID ADD09373 standard; cDNA; 1174 BP.
XX

AC ADD09373;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194775-A1.
XX
PD 16-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156848.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852595/79.
DR P-PSDB; ADD09374.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha from blood and stimulating the release of proteoglycans from
PT cartilage.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
```

```
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 138
ADD41086
ID ADD41086 standard; cDNA; 1174 BP.
XX
AC ADD41086;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203438-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146786.
XX
PR 24-NOV-1997; 97US-0066511P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875645/81.
DR P-PSDB; ADD41087.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 139
ADD52225
ID ADD52225 standard; cDNA; 1174 BP.
XX
AC ADD52225;
XX
DT 15-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194769-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152374.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852593/79.
DR P-PSDB; ADD52226.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for detection of tumors, modulating the uptake of glucose
PT or free fatty acids and stimulating the release of proteoglycans from
PT cartilage.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 9; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 140
ADD52965
ID   ADD52965 standard; cDNA; 1174 BP.
XX
AC   ADD52965;
XX
DT   15-JAN-2004  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194792-A1.
XX
PD   16-OCT-2003.
XX
PF   15-APR-2002; 2002US-00123156.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
```

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852599/79.
DR P-PSDB; ADD52966.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
```

```
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 141
ADD53517
ID ADD53517 standard; cDNA; 1174 BP.
XX
AC ADD53517;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203437-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146728.
XX
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUN-1999; 99WO-US012252.
PR 01-DEC-2000; 2000US-00380137.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875644/81.
DR P-PSDB; ADD53518.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
```

```
Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 142
ADD37049
ID ADD37049 standard; cDNA; 1174 BP.
XX
AC ADD37049;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane PRO polypeptide cDNA #4.
XX
KW ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX
OS Homo sapiens.
XX

PN US2003105012-A1.
XX
PD 05-JUN-2003.
XX
PF 16-AUG-2002; 2002US-00223088.
XX
PR 15-SEP-2000; 2000US-0232887P.
PR 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2003-829354/77.
DR P-PSDB; ADD37050.
XX
PT New isolated nucleic acids encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.
XX
PS Claim 2; SEQ ID NO 7; 492pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGF-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
```

```
Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 143
ADD51673
ID ADD51673 standard; cDNA; 1174 BP.
XX
AC ADD51673;
XX
DT 15-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194779-A1.
XX
PD 16-OCT-2003.
XX
PF 30-MAY-2002; 2002US-00160500.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852597/79.
DR P-PSDB; ADD51674.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting the presence of a tumor, stimulating the release of tumor
PT necrosis factor alpha from human blood and treating, e.g. organ failure.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match   100.0%; Score 1174; DB 9; Length 1174;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1174; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
```

```
Db       1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy      61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy     121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy     181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy     241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy     301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy     361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy     421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy     481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy     541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy     601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy     661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy     721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy     781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy     841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy     901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy     961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy    1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy    1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db    1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy    1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
           |||||||||||||||||||||||||||||||||||
Db    1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 144
ADD02472
ID   ADD02472 standard; cDNA; 1174 BP.
XX
AC   ADD02472;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003203431-A1.
XX
PD   30-OCT-2003.
XX
PF   24-APR-2002; 2002US-00131820.
XX
PR   28-OCT-1998;   98US-0106030P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   24-AUG-2000; 2000WO-US023328.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-875638/81.
DR   P-PSDB; ADD02473.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
```

CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 145
ADD01906
ID ADD01906 standard; cDNA; 1174 BP.
XX
AC ADD01906;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203430-A1.
XX
PD 30-OCT-2003.
XX
PF 23-APR-2002; 2002US-00128685.
XX
PR 11-AUG-1998; 98US-0096143P.
PR 02-JUN-1999; 99WO-US012252.
PR 30-MAR-2000; 2000US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875637/81.
DR P-PSDB; ADD01907.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 146
ADD54088
ID ADD54088 standard; cDNA; 1174 BP.
XX
AC ADD54088;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203432-A1.
XX
PD 30-OCT-2003.
XX
PF 10-MAY-2002; 2002US-00142886.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875639/81.
DR P-PSDB; ADD54089.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
```

```
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 147
ADE49363
ID   ADE49363 standard; cDNA; 1174 BP.
XX
AC   ADE49363;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003096744-A1.
XX
PD   22-MAY-2003.
XX
PF   28-JAN-2002; 2002US-00978187.
XX
PR   17-OCT-1997;   97US-0062250P.
PR   03-NOV-1997;   97US-0064249P.
PR   13-NOV-1997;   97US-0065311P.
PR   21-NOV-1997;   97US-0066364P.
PR   10-MAR-1998;   98US-0077450P.
PR   11-MAR-1998;   98US-0077632P.
PR   11-MAR-1998;   98US-0077641P.
PR   11-MAR-1998;   98US-0077649P.
PR   12-MAR-1998;   98US-0077791P.
PR   13-MAR-1998;   98US-0078004P.
PR   17-MAR-1998;   98US-00040220.
PR   20-MAR-1998;   98US-0078886P.
PR   20-MAR-1998;   98US-0078910P.
PR   20-MAR-1998;   98US-0078936P.
PR   20-MAR-1998;   98US-0078939P.
PR   25-MAR-1998;   98US-0079294P.
PR   26-MAR-1998;   98US-0079656P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079664P.
PR   27-MAR-1998;   98US-0079689P.
PR   27-MAR-1998;   98US-0079728P.
PR   27-MAR-1998;   98US-0079786P.
PR   30-MAR-1998;   98US-0079920P.
PR   30-MAR-1998;   98US-0079923P.
PR   31-MAR-1998;   98US-0080105P.
PR   31-MAR-1998;   98US-0080165P.
PR   31-MAR-1998;   98US-0080194P.
PR   01-APR-1998;   98US-0080327P.
PR   01-APR-1998;   98US-0080328P.
PR   01-APR-1998;   98US-0080333P.
PR   01-APR-1998;   98US-0080334P.
PR   08-APR-1998;   98US-0081049P.
PR   08-APR-1998;   98US-0081070P.
PR   08-APR-1998;   98US-0081071P.
PR   09-APR-1998;   98US-0081195P.
PR   09-APR-1998;   98US-0081203P.
PR   09-APR-1998;   98US-0081229P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081819P.
PR   15-APR-1998;   98US-0081838P.
PR   15-APR-1998;   98US-0081952P.
PR   15-APR-1998;   98US-0081955P.
PR   21-APR-1998;   98US-0082568P.
PR   21-APR-1998;   98US-0082569P.
PR   22-APR-1998;   98US-0082700P.
PR   22-APR-1998;   98US-0082704P.
PR   22-APR-1998;   98US-0082797P.
PR   22-APR-1998;   98US-0082804P.
PR   23-APR-1998;   98US-0082796P.
PR   27-APR-1998;   98US-0083336P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083392P.
PR   29-APR-1998;   98US-0083495P.
PR   29-APR-1998;   98US-0083496P.
PR   29-APR-1998;   98US-0083499P.
PR   29-APR-1998;   98US-0083500P.
PR   29-APR-1998;   98US-0083545P.
PR   29-APR-1998;   98US-0083554P.
PR   29-APR-1998;   98US-0083558P.
PR   29-APR-1998;   98US-0083559P.
PR   30-APR-1998;   98US-0083742P.
PR   05-MAY-1998;   98US-0084366P.
PR   06-MAY-1998;   98US-0084414P.
PR   06-MAY-1998;   98US-0084441P.
PR   07-MAY-1998;   98US-0084598P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   07-MAY-1998;   98US-0084639P.
PR   07-MAY-1998;   98US-0084640P.
PR   07-MAY-1998;   98US-0084643P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085573P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085580P.
PR   15-MAY-1998;   98US-0085582P.
PR   15-MAY-1998;   98US-0085689P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085700P.
PR   15-MAY-1998;   98US-0085704P.
PR   18-MAY-1998;   98US-0086023P.
PR   22-MAY-1998;   98US-0086392P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   22-MAY-1998;   98US-0086486P.
PR   28-MAY-1998;   98US-0087098P.
PR   28-MAY-1998;   98US-0087106P.
PR   28-MAY-1998;   98US-0087208P.
PR   26-JUN-1998;   98US-00105413.
PR   26-JUN-1998;   98US-0090863P.
PR   26-JUN-1998;   98US-0091010P.
PR   01-JUL-1998;   98US-0091359P.
PR   30-JUL-1998;   98US-0094651P.
PR   11-SEP-1998;   98US-0100038P.
PR   07-OCT-1998;   98US-00168978.
PR   07-OCT-1998;   98WO-US021141.
PR   02-NOV-1998;   98US-00184216.
PR   06-NOV-1998;   98US-00187368.
PR   20-NOV-1998;   98US-0109304P.
PR   20-NOV-1998;   98WO-US024855.
PR   07-DEC-1998;   98US-00202054.
PR   22-DEC-1998;   98US-00218517.
PR   22-DEC-1998;   98US-0113296P.
PR   23-DEC-1998;   98US-0113621P.
PR   05-JAN-1999;   99WO-US000106.
PR   05-MAR-1999;   99US-00254465.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99US-00265686.
PR   10-MAR-1999;   99WO-US005190.
PR   12-MAR-1999;   99US-00267213.
PR   12-MAR-1999;   99US-0123957P.
PR   29-MAR-1999;   99US-0126773P.
PR   12-APR-1999;   99US-00284291.
PR   21-APR-1999;   99US-0130232P.
PR   26-APR-1999;   99US-0131022P.
PR   28-APR-1999;   99US-0131445P.
PR   14-MAY-1999;   99US-00311832.
```

```
PR   14-MAY-1999;   99US-0134287P.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   16-JUN-1999;   99US-0139557P.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0142680P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   25-AUG-1999;   99US-00380137.
PR   25-AUG-1999;   99US-00380138.
PR   25-AUG-1999;   99US-00380142.
PR   29-OCT-1999;   99US-0162506P.
PR   30-NOV-1999;   99WO-US028313.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000US-00709238.
PR   27-NOV-2000; 2000US-00723749.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001WO-US006520.
PR   22-MAR-2001; 2001US-00816744.
PR   22-MAR-2001; 2001US-00816920.
PR   22-MAR-2001; 2001WO-US009552.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   30-JUL-2001; 2001US-00918585.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174

RESULT 148
```

```
ADD92405
ID   ADD92405 standard; cDNA; 1174 BP.
XX
AC   ADD92405;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199030-A1.
XX
PD   23-OCT-2003.
XX
PF   28-MAY-2002; 2002US-00156841.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-900159/82.
DR   P-PSDB; ADD92406.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 2; SEQ ID NO 271; 636pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
```

```
Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 149
ADD91301
ID ADD91301 standard; cDNA; 1174 BP.
XX
AC ADD91301;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199055-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121063.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900165/82.
DR P-PSDB; ADD91302.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 271; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 150
ADE03915
ID ADE03915 standard; cDNA; 1174 BP.
XX
AC ADE03915;

XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199057-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123213.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900167/82.
DR P-PSDB; ADE03916.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

```
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match           100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity  100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 151
ADE32212
ID   ADE32212 standard; cDNA; 1174 BP.
XX
AC   ADE32212;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW   Human; secreted and transmembrane protein; PRO; gene; ss;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inhibitor; cytokine release stimulator; tumour;
KW   lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003194765-A1.
XX
PD   16-OCT-2003.
XX
PF   09-MAY-2002; 2002US-00142889.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
```

XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899784/82.
DR P-PSDB; ADE32213.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 271; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 152
ADE22144
ID ADE22144 standard; cDNA; 1174 BP.
XX
AC ADE22144;
XX
DT 29-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199056-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123212.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900166/82.
DR P-PSDB; ADE22145.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

```
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence encodes a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

```
RESULT 153
ADD79368
ID   ADD79368 standard; cDNA; 1174 BP.
XX
AC   ADD79368;
XX
DT   29-JAN-2004  (first entry)
XX
DE   cDNA encoding human PRO polypeptide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003203428-A1.
XX
PD   30-OCT-2003.
XX
PF   22-APR-2002; 2002US-00127852.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-875635/81.
DR   P-PSDB; ADD79369.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
```

PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy 1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 154
ADE35417
ID ADE35417 standard; cDNA; 1174 BP.
XX
AC ADE35417;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnerary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003203434-A1.

XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145088.
XX
PR 15-MAY-1998; 98US-0085689P.
PR 08-MAR-1999; 99WO-US005028.
PR 28-APR-1999; 99US-0131445P.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-875641/81.
DR P-PSDB; ADE35418.
XX
PT New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for treating e.g. lung or breast tumors, osteoarthritis,
PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT hypoinsulinemia or wounds.
XX
PS Claim 2; SEQ ID NO 329; 462pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db    1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db   61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
Db  121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db  181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db  241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db  301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db  361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db  421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db  481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db  541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
Db  601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
Db  661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
Db  721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
Db  781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db  841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db  901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db  961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
```

```
                  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
                  ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 155
ADE16531
ID   ADE16531 standard; cDNA; 1174 BP.
XX
AC   ADE16531;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW   Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW   cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW   vulnerary; auditory; tumour growth; retinal disorder;
KW   sports-related joint problem; articular cartilage defects;
KW   osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS   Homo sapiens.
XX
PN   US2003203435-A1.
XX
PD   30-OCT-2003.
XX
PF   18-OCT-2001; 2001US-00145092.
XX
PR   30-APR-1998;   98US-0083742P.
PR   08-MAR-1999;   99WO-US005028.
PR   23-JUN-1999;   99US-0141037P.
PR   25-AUG-1999;   99US-00380138.
PR   18-FEB-2000; 2000WO-US004341.
PR   30-JUL-2001; 2001US-00918585.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME;
PI   Goddard A,  Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ;
PI   Kljavin IJ,  Kuo SS,  Napier MA,  Pan J,  Paoni NF,  Roy MA,  Shelton DL;
PI   Stewart TA,  Tumas D,  Williams PM,  Wood WI;
XX
DR   WPI; 2003-875642/81.
DR   P-PSDB; ADE16532.
XX
PT   New genes, and its encoded secreted and transmembrane polypeptides,
PT   useful for treating e.g. lung or breast tumors, osteoarthritis,
PT   rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT   hypoinsulinemia or wounds.
XX
PS   Claim 2; SEQ ID NO 329; 452pp; English.
XX
CC   The invention relates to an isolated PRO polypeptide (secreted or
CC   transmembrane protein) having at least 80% amino acid sequence identity
CC   to an amino acid sequence chosen from 94 fully defined sequences as given
CC   in the specification (including PRO lacking its associated signal
CC   peptide, a PRO extracellular domain with or without its associated signal
CC   peptide). Also included are nucleic acids encoding the PRO proteins
CC   mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC   comprising the vector and producing PRO, a chimaeric molecule comprising
CC   PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC   antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC   polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC   Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC   polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC   PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC   PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC   bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC   molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC   causes death of the cell. PRO337 polypeptide is useful for linking a
CC   bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC   PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC   to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC   useful for linking a bioactive molecule to a cell expressing PRO725,
CC   PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC   polypeptide is useful for modulating at least one biological activity of
CC   the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC   polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC   biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC   PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC   modulating the biological activity of the cell expressing PRO1559
CC   polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC   PRO739 polypeptide is useful for modulating the biological activity of
CC   the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC   polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC   sports-related joint problems, articular cartilage defects,
CC   osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC   mammals. The present sequence encodes a PRO protein.
XX
SQ   Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 1174;  DB 9;  Length 1174;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 1174;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              |||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
```

RESULT 156
ADD73146
ID ADD73146 standard; cDNA; 1174 BP.
XX
AC ADD73146;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnerary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003203436-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145129.
XX
PR 22-MAY-1998; 98US-0086414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-APR-1999; 99US-00284291.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-875643/81.
DR P-PSDB; ADD73147.
XX
PT New PRO genes and encoded secreted and transmembrane polypeptides, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT wounds.
XX
PS Claim 2; SEQ ID NO 329; 453pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy           1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy          61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy         121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy         181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240

Qy         241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
```

```
Db        241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

Qy        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

Qy        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC 540

Qy        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660

Qy        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAATGAGAAATTCACAAGCG 720

Qy        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTAAGATGCCTCTCTCTTAAC 780

Qy        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Qy        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

Qy        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAAGACAAGTGTAATAGACATCTAA 1080

Qy       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AATTCCACTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Qy       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174
              ||||||||||||||||||||||||||||||||||
Db       1141 CTATAAAATGCAAATAAAGTTACTCAAATCTGTG 1174


RESULT 157
ADE41904
ID   ADE41904 standard; cDNA; 1174 BP.
XX
AC   ADE41904;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polynucleotide #136.
XX
KW   Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194772-A1.
XX
PD   16-OCT-2003.
XX
PF   21-MAY-2002; 2002US-00152386.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-899788/82.
DR   P-PSDB; ADE41905.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 2; Fig 271; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polynucleotide of the invention. Note:
CC   The sequence data for this patent is also available in electronic format
CC   from USPTO at seqdata.uspto.gov/sequence.html.
XX
```